REVIEW article

Front. Pharmacol., 24 January 2022

Sec. Ethnopharmacology

Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.795565

Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology

  • 1. The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China

  • 2. Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Article metrics

View details

31

Citations

7,3k

Views

2,4k

Downloads

Abstract

Limonoids, as the vital bioactive chemical compounds in genus Melia plants, have attracted significant attention owing to their exclusive structural characteristics and remarkable biological activity. These compounds can be usually classified into two categories, including the ring-intact group and the ring-C-seco group. Benefiting from the development of separation and analysis technology, more than 200 limonoids have been isolated and identified from this genus. There is growing evidence that limonoids from genus Melia possess diverse pharmacological activities, especially anti-cancer effects, insecticidal activities, and anti-botulism effects. Toosendanin, one of the paramount limonoids, was considered as the pivotal bioactive marker in two medicinal herbs, including Melia toosendan Sieb. et Zucc and Melia azedarach L. In particular, limonoids are found to exhibit non-negligible toxic effects, a finding which needs further research. Besides this, the lack of clinical research data seriously hinders its further development and utilization, and necessary clinical trials should be taken into consideration. In this review, we systematically summarized the phytochemical compounds and their synthesis methods, pharmacological activities, and the structure–activity relationship, pharmacokinetics, and toxicology of genus Melia-derived limonoids. We believe that this up-to-date review could provide scientific evidence for the application of limonoids as agents beneficial to health in future clinical practice.

Introduction

Genus Melia, a model genus of Meliaceae, has about 20 species in the world and is widely distributed in tropical and subtropical regions of the Eastern Hemisphere. Among them, Melia toosendan Sieb. et Zucc., Melia azedarach L., Melia azedarach var. japonica, and Melia volkensii Gürke have received a lot of attention (Liu et al., 2010). It is worth noting that Azadirachta indica A. Juss., a plant of the genus Azadirachta, is often wrongly recognized as M. azedarach L. for their similar morphological characteristics and botanical name (Saleem et al., 2018). Owing to their multiple bioactivities, the Melia plants have been used as folk herbs in treating leprosy, eczema, asthma, malaria, fever, and pain (Xie et al., 2008). M. toosendan Sieb. et Zucc and M. azedarach L., two common medicinal plants in China, have been used to treat diseases for thousands of years. The first traditional usage can be traced back to Shen Nong Ben Cao Jing, which is the earliest medical monograph in China that was written during the Eastern Han Dynasty (AD 25–220). In this monograph, the two herbs functioned as treatment for anxiety, destroying parasites, and promoting diuresis. According to Ben Cao Gang Mu (AD 1578), which is another famous medical classic, M. toosendan and M. azedarach could treat stomach ache and hernia. In addition, the ability to clear heat and promote diuresis was reported in Ben Cao Jing Shu (AD 1625). According to Chinese Pharmacopoeia, M. toosendan and M. azedarach have been recorded as insecticide and painkiller (Chinese Pharmacopoeia Commission, 2020). Various types of chemical compounds have been isolated and identified from different parts of genus Melia plants, including limonoids (triterpenoids), steroids, alkaloids, flavonoids, anthraquinones, etc. (Zhao et al., 2010). Modern pharmacological research demonstrated that limonoids, which are abundant in Melia species, exhibit a potential activity (Taylor, 1984). The word “limonoids” originated from the bitterness of lemon or other citrus fruits. Early chemical research of such compounds in Meliaceae started in 1960. The first limonoid compound named gedunin was isolated from wood of the West African plant Entandrophragma angolense, and its chemical structure was identified by comparison with limonin (Goerlich, 1960). The fundamental structure of limonoids is formed by the loss of four terminal carbons of the side chain in the apotirucallane or apoeuphane skeleton and then cyclized to form the 17β-furan ring, and thus limonoids are also known as tetranortriterpenoids (Tan and Luo, 2011). In this paper, a literature survey was carried out by searching the keywords including “limonoids”, “Melia”, “Melia toosendan Sieb. et Zucc”, and “Melia azedarach L.” from Pubmed, SciFinder, Science Direct, Scopus, the Web of Science, Google Scholar, China National Knowledge Infrastructure, and classic books of herbal medicine. All data were searched up to May 2021 to identify eligible studies. Some previous reviews have summarized the limonoids-related research progresses—for instance, the chemical compounds of Melia species and their bioactivities were summarized in 2010 (Zhao et al., 2010). In addition, a fantastic review has comprehensively covered the limonoids from Meliaceae, and their pharmacological effects were also concluded (Tan and Luo, 2011). Nevertheless, our work attempts to offer some constructive information that is favorable to the development of genus Melia-derived limonoids that originated from traditional medicinal herbs. Herein we systematically summarize the phytochemistry, synthesis, pharmacological activities, structure–activity relationships, pharmacokinetics, and safety aspects of limonoids, hoping that these could propel forward the exploration for this kind of valuable compound. Furthermore, the future research perspectives and difficulties are discussed as well.

Chemical Compounds

After years of phytochemical research, more than 200 limonoids have been isolated and identified from genus Melia plants. As expected, the majority of these compounds originated from M. toosendan and M. azedarach because these two species are commonly used as medicinal herbs. In addition, the distribution of these compounds also varied in different parts of the plants, of which the fruit, bark, and root bark possessed higher content. Interestingly, those parts mentioned above are consistent with the medicinal parts of M. toosendan and M. azedarach. Therefore, isolation of bioactive compounds from medicinal herbs is a promising strategy for discovering lead compounds in drug development. At present, it is generally acknowledged that the precursors for the biogenic synthesis of limonoids are two types of tetracyclic triterpenoids, including tirucallane and euphane. The biosynthesis pathways of limonoids are shown in Figure1. Firstly, the Δ7-double bond is oxidized to 7-epoxy, which was subsequently opened to cause a Wagner–Meerwein shift of Me-14 to C-8, and finally leads to the formation of OH-7 and the introduction of a double bond at C-14/15. On this basis, four carbons are lost from the rear side chain to form a 17-β-furan ring, and the last step is finished after the formation of the 4,4,8-trimethyl-steroid skeleton, which was regarded as the basic limonoid skeleton (Tan and Luo, 2011). The limonoids in genus Melia are mainly classified into two classes, including the ring-intact limonoids and the ring-C-seco limonoids, and the detailed chemical information will be discussed in this review (Table 1).

FIGURE 1

FIGURE 1

Proposed major biosynthesis pathways of limonoids in genus Melia.

TABLE 1

NoCompoundsPart of plantSourcesReference
Trichilin class
1Azedarachin AStem barksM. toosendanZhou et al. (1996)
212-O-Acetylazedarachin ARoot barksM. toosendanNakatani (1999)
312-O-Acetylazedarachin BStem barksM. toosendanZhou et al. (1996)
4Azedarachin CRoot barksM. azedarachD'Ambrosio and Guerriero (2002)
5Azedarachin BRoot barksM. toosendanNakatani (1999)
6SendaninStem and root barksM. toosendanNakatani (1999)
712-HydroxyamoorastatinRoot barksM. toosendanNakatani (1999)
8ToosendaninStem barksM. toosendanZhang et al. (2010c)
912-O-Deacetyltrichilin HFruitsM. azedarachZhou et al. (2005)
1012-Acetyltrichilin BRoot barksM. azedarachNakatani et al. (1994)
117,12-Diacetyltrichilin BRoot barksM. azedarachNakatani et al. (1994)
12Trichilin HStem barksM. toosendanZhou et al. (1996)
13Trichilin BRoot barksM. toosendanNakatani (1999)
14Trichilin DRoot barksM. azedarachNakatani et al. (1994)
15Meliatoxin A2Root barksM. azedarachNakatani et al. (1994)
16Trichilin KStem barksM. toosendanZhou et al. (1996)
17Trichilin LStem barksM. toosendanZhou et al. (1996)
18Trichilin IStem barksM. toosendanZhou et al. (1996)
19Trichilin JStem barksM. toosendanZhou et al. (1996)
2012-Deacetyltrichilin IBarksM. azedarachTakeya et al. (1996b)
211-Acetyltrichilin HBarksM. azedarachTakeya et al. (1996b)
223-Deacetyltrichilin HBarksM. azedarachTakeya et al. (1996b)
231-Acetyl-3-deacetyltrichilin HBarksM. azedarachTakeya et al. (1996b)
241-Acetyl-2-deacetyltrichilin HBarksM. azedarachTakeya et al. (1996b)
251,12-Diacetyltrichilin BBarksM. azedarachTakeya et al. (1996b)
26Meliatoosenin CStem barksM. toosendanZhang et al. (2010c)
2724-Norchola-20,22-diene-4-carboralde-hyde-14,15:21,23-diepoxy-1,3,7,12,19-pentachydroxy-4,8-dimethyl-11-oxo-cyclic-4,19-hemiacetal[C(S),1α,3α,4β,5α,7α,12α,13α,14β,15β,17α]-(9Cl)Stem barksM. toosendanZhang et al. (2010c)
28Meliatoosenin DStem barksM. toosendanZhang et al. (2010c)
291-O-Acetyltrichilin HRoot barksM. toosendanZhou et al. (1998)
3012-AcetoxyamoorastatinBarksM. azedarachAhn et al. (1994)
317-BenzoyltoosendaninSeedsM. azedarachLiu et al. (2011)
327-CinnamoyltoosendaninSeedsM. azedarachLiu et al. (2011)
33Meliarachin BTwigs and leavesM. azedarachSu et al. (2011)
34Meliarachin CTwigs and leavesM. azedarachSu et al. (2011)
35Meliatoxin B1FruitsM. toosendanTada et al. (1999)
3612α-Hydroxymeliatoxin B1FruitsM. toosendanZhu et al. (2014)
3712α-Acetoxylmeliatoxin B2FruitsM. toosendanZhu et al. (2014)
38Meliatoosenin GFruitsM. toosendanZhang et al. (2012)
39Meliatoosenin HFruitsM. toosendanZhang et al. (2012)
4029-[(2-Methylbutanoyl)oxy]-2α-hydroxyamoorastatoneRoot barksM. toosendanZhou et al. (2009)
411,3-epi-29-[(2-Methylpropanoyl)oxy]-2α-hydroxyamoorastatoneRoot barksM. toosendanZhou et al. (2009)
42IsotoosendaninFruitsM. toosendanXie et al. (2008)
43Meliarachin LFruitsM. toosendanYan et al. (2020)
44Neoazedarachin ARoot barksM. toosendanZhou et al. (1998)
45Neoazedarachin BRoot barksM. toosendanZhou et al. (1998)
46Neoazedarachin DRoot barksM. toosendanZhou et al. (1998)
4712α-HydroxyamoorastatoneRoot barksM. toosendanZhou et al. (1998)
48AmoorastatoneFruitsM. toosendanWang et al. (2020a)
4912-Dehydroneoazedarachin DFruitsM. azedarachAkihisa et al. (2013)
50Meliatoxin B2BarksM. azedarachHuang et al. (1994)
51Meliarachin GTwigs and leavesM. azedarachSu et al. (2011)
52Meliarachin HTwigs and leavesM. azedarachSu et al. (2011)
53Meliarachin ITwigs and leavesM. azedarachSu et al. (2011)
54Meliarachin JTwigs and leavesM. azedarachSu et al. (2011)
55Meliarachin KTwigs and leavesM. azedarachSu et al. (2011)
5612α-Hydroxymeliatoosenin IFruitsM. toosendanZhu et al. (2014)
57Meliatoosenin IFruitsM. toosendanZhang et al. (2012)
58Meliatoosenin JFruitsM. toosendanZhang et al. (2012)
59Mesendanin HTwigs and leavesM. toosendanDong et al. (2010)
60Meliarachin DTwigs and leavesM. azedarachSu et al. (2011)
61Meliarachin ETwigs and leavesM. azedarachSu et al. (2011)
62Meliazedalides BFruitsM. azedarachQiu et al. (2019)
63ToosendalactoninsFruitsM. azedarachPark et al. (2020)
64Meliatoosenin EFruitsM. toosendanZhang et al. (2012)
65Mesendanin GTwigs and leavesM. toosendanDong et al. (2010)
66MeliarteninFruitsM. azedarachCarpinella et al. (2003)
67ToosendanalFruitsM. toosendanTada et al. (1999)
Vilasinin class
68Meliatoosenin KFruitsM. toosendanZhang et al. (2012)
69Trichilinin DRoot barksM. toosendanNakatani (1999)
70Trichilinin ERoot barksM. toosendanNakatani (1999)
71Toosendansin HFruitsM. toosendanLi et al. (2020b)
721-O-cinnamoyltrichilininFruitsM. toosendanNakatani et al. (2000)
73Trichilinin BRoot barksM. toosendanNakatani (1999)
74Trichilinin CRoot barksM. toosendanNakatani (1999)
7524, 25,26, 27-Tetranorapotirucalla-(apoeupha)-1α-tigloyloxy-3α, 7α-dihydroxyl-12α-acetoxyl-14, 20, 22-trien-21, 23-epoxy-6,28-epoxyFruitsM. toosendanZhang et al. (2010d)
76MeliavolkinBarksM. volkensiiZeng et al. (1995a)
77MeliavolkininBarksM. volkensiiRogers et al. (1998a)
781,3-DiacetylvilasininBarksM. volkensiiRogers et al. (1998a)
791-AcetyltrichilininFruitsM. volkensiiJaoko et al. (2020)
801-TigloyltrichilininFruitsM. volkensiiJaoko et al. (2020)
8111,15-DioxotrichilininFruitsM. toosendanZhu et al. (2014)
82Toosendansin IFruitsM. toosendanLi et al. (2020b)
Havanensin class
83Mesendanin CTwigs and leavesM. toosendanDong et al. (2010)
84Mesendanin DTwigs and leavesM. toosendanDong et al. (2010)
85Sendanal BFruitsM. toosendanYan et al. (2020)
8624,25,26,27-Tetra-norapotirucalla-(apoeupha)-1α,6α,12α-triacetoxyl-3α,7α-dihydroxyl-28-aldehyde-14,20,22-trien-21,23-epoxyFruitsM. toosendanZhang et al. (2013)
8714,15-Deoxy-11-oxohavanensin 3,12-diacetateFruitsM. toosendanZhu et al. (2014)
88Mesendanin ATwigs and leavesM. toosendanDong et al. (2010)
89Mesendanin BTwigs and leavesM. toosendanDong et al. (2010)
90Mesendanin JTwigs and leavesM. toosendanDong et al. (2010)
91ToosendoneFruitsM. toosendanZhang et al. (2007)
92ButenolideRoot barksM. toosendanNakatani (1999)
93Meliarachin ATwigs and leavesM. azedarachSu et al. (2011)
94Melianin CBarksM. volkensiiRogers et al. (1998a)
95Meliatoosenin FFruitsM. toosendanZhang et al. (2012)
96Mesendanin ITwigs and leavesM. toosendanDong et al. (2010)
Azadirone class
97Meliatoosenin AStem barksM. toosendanZhang et al. (2010c)
98AzadironeRoot barksM. toosendanNakatani (1999)
99AcetyltrichilenoneRoot barksM. toosendanNakatani (1999)
Nimbolinin class
10012-O-MethylvolkensinFruitsM. toosendanTada et al. (1999)
1011-Deacetylnimbolinin ARoot barksM. toosendanNakatani et al. (1999)
102Nimbolinin AFruitsM. toosendanSu et al. (2013)
103Nimbolinin CFruitsM. toosendanNakatani et al. (2000)
104Nimbolinin DFruitsM. toosendanNakatani et al. (2000)
105Nimbolinin BFruitsM. toosendanSu et al. (2013)
1061-Deacetylnimbolinin BFruitsM. toosendanSu et al. (2013)
10712-Ethoxynimbolinins AFruitsM. toosendanZhang et al. (2007)
10812-Ethoxynimbolinins BFruitsM. toosendanZhang et al. (2007)
10912-Ethoxynimbolinins CFruitsM. toosendanZhang et al. (2007)
11012-Ethoxynimbolinins DFruitsM. toosendanZhang et al. (2007)
11112-Ethoxynimbolinins HBarksM. toosendanZhang et al. (2018)
112Nimbolin BRoot barksM. volkensiiZeng et al. (1995b)
1131-Decinnamoyl-1-(2′-methylacryloyl) nimbolinin CFruitsM. toosendanZhu et al. (2014)
1141-Decinnamoylnimbolinin CFruitsM. toosendanZhu et al. (2014)
11512-O-Methyl-1-O-deacetylnimbolinin BFruitsM. toosendanHu et al. (2011)
11612-O-Methyl-1-O-tigloyl-1-O-deacetylnimbolinin BFruitsM. toosendanHu et al. (2011)
11712-O-Ethylnimbolinin BFruitsM. toosendanHu et al. (2011)
1181α, 7α-Dihydroxyl-3α-acetoxyl-12α-ethoxylnimbolininFruitsM. toosendanZhang et al. (2016)
1191α-Tigloyloxy-3α-acetoxyl-7α-hydroxyl-12β-ethoxylnimbolininFruitsM. toosendanZhang et al. (2016)
1201α, 3α-Dihydroxyl-7α-tigloyloxy-12α-ethoxylnimbolininFruitsM. toosendanZhang et al. (2016)
1211α, 7α-Ditigloyloxy-3α-acetoxyl-12α-ethoxylnimbolininFruitsM. toosendanZhang et al. (2016)
1221α-Benzoyloxy-3α-acetoxyl-7α-hydroxyl-12β-ethoxylnimbolininFruitsM. toosendanZhang et al. (2013)
12312α-1-O-Tigloyl-1-O-deacetyl-nimbolinin BFruitsM. toosendanSu et al. (2013)
1241α-Benzoyloxy-3α-acetoxyl-7α-hydroxyl-12α-ethoxyl nimbolininFruitsM. toosendanZhang et al. (2010b)
1251-O-Benzoyl-3-O-deactylnim-bolinin CFruitsM. azedarachPark et al. (2020)
1261-Benzoylnimbolinin CSeedsM. azedarachLiu et al. (2011)
127Meliatoosenin LFruitsM. toosendanZhang et al. (2012)
128Meliatoosenin NFruitsM. toosendanZhang et al. (2012)
129Toosendansins BFruitsM. toosendanChen et al. (2014)
1303-Deacetyl-12-O-methylvolkensinFruitsM. toosendanZhu et al. (2014)
131Meliatoosenin TFruitsM. toosendanYan et al. (2020)
132Meliatoosenin UFruitsM. toosendanYan et al. (2020)
133Meliazedalides AFruitsM. azedarachQiu et al. (2019)
Ohchinolide class
134Ohchinolide AFruitsM. azedarachOchi et al. (1979)
135Ohchinolide BRoot barksM. toosendanZhou et al. (1997)
136Ohchinolide CBarksM. toosendanZhou et al. (1997)
1371-O-Deacetyl-1-O-tigloylohchinolide BFruitsM. azedarachZhou et al. (2004)
1381-O-Deacetyl-1-O-benzoylohchinolide BFruitsM. azedarachZhou et al. (2004)
1391-O-Deacetyl-1-O-tigloylohchinolide AFruitsM. azedarachZhou et al. (2004)
1401-O-Deacetylohchinolide BFruitsM. azedarachZhou et al. (2004)
1411-O-Deacetylohchinolide AFruitsM. azedarachZhou et al. (2004)
142Azecin 2RootsM. azedarachTan and Luo (2011)
Nimbolidin class
143Nimbolidin FBarksM. toosendanZhou et al. (1997)
144Nimbolidin DBarksM. toosendanZhou et al. (1997)
145Nimbolidin CRoot barksM. toosendanNakatani et al. (1996)
146Nimbolidin ERoot barksM. toosendanNakatani et al. (1996)
147Nimbolidin BRoot barksM. toosendanNakatani et al. (1996)
14815-O-Deacetyl-15-O-methylnimbolidin AFruitsM. azedarachZhou et al. (2005)
14915-O-Deacetyl-15-O-methylnimbolidin BFruitsM. azedarachZhou et al. (2005)
15015-O-Deacetylnimbolidin BFruitsM. azedarachZhou et al. (2005)
Salannin class
1511-O-Cinnamoyl-1-O-debenzoylohchinalFruitsM. toosendanHu et al. (2011)
1521-O-Tigloyl-1-O-debenzoylohchinalFruitsM. toosendanHu et al. (2011)
153SalanninRoot barksM. toosendanNakatani et al. (1996)
1543-O-DeacetylsalanniFruitsM. azedarachAkihisa et al. (2013)
155OhchinalFruitsM. toosendanWang et al. (2020a)
156OhchininLeavesM. azedarachPan et al. (2014b)
1571-O-Decinnamoyl-1-O-benzoylohchininFruitsM. azedarachAkihisa et al. (2013)
1583-Deacetyl-4′-demethylsalanninFruitsM. azedarachPan et al. (2014a)
1593-Deacetyl-3-tigloylsalanninFruitsM. azedarachAkihisa et al. (2017)
1602′,3′-DihydrosalanninFruitsM. volkensiiJaoko et al. (2020)
1611-Detigloyl-1-isobutylsalanninFruitsM. volkensiiJaoko et al. (2020)
162Ohchinin-acetateFruitsM. volkensiiJaoko et al. (2020)
163OhchininolideFruitsM. azedarachAkihisa et al. (2013)
1641-O-Decinnamoyl-1-O-benzoylohchininolideFruitsM. azedarachAkihisa et al. (2013)
16523-HydroxyohchininolideLeavesM. azedarachPan et al. (2014b)
16623-Methoxyohchininolide AFruitsM. azedarachAkihisa et al. (2013)
1671-O-Decinnamoyl-1-O-benzoyl-23-hydroxyohchininolideFruitsM. azedarachAkihisa et al. (2013)
1683-Deacetyl-28-oxosalanninLeavesM. azedarachPan et al. (2014b)
1693-Deacetyl-4′-demethyl-28-oxosalanninLeavesM. azedarachPan et al. (2014b)
1701-O-Decinnamoyl-1-O-benzoyl-28-oxoohchininFruitsM. azedarachAkihisa et al. (2013)
1713-Deacetyl-28-oxosalannolactoneLeavesM. azedarachPan et al. (2014b)
1723-Deacetyl-28-oxoisosalanninolideLeavesM. azedarachPan et al. (2014b)
1733-Deacetyl-17-defurano-17,28-dioxosalanninLeavesM. azedarachPan et al. (2014b)
17421-HydroxyisoohchininolideLeavesM. azedarachAkihisa et al. (2013)
17517-Defurano-17-oxoohchininFruitsM. azedarachAkihisa et al. (2013)
176Meliatoosenin PFruitsM. toosendanZhang et al. (2012)
177Meliatoosenin QFruitsM. toosendanZhang et al. (2012)
Ohchinolal class
1783-O-AcetylohchinolalBarksM. toosendanZhou et al. (1997)
1791-DetigloylohchinolalFruitsM. azedarachPan et al. (2014a)
1801-Benzoyl-1-detigloylohchinolalFruitsM. azedarachAkihisa et al. (2017)
1811-Cinnamoyl-1-detigloylohchinolalFruitsM. azedarachAkihisa et al. (2017)
182OhchinolalRoot barksM. toosendanZhou et al. (1997)
183Mesendanin EFruitsM. azedarach(Dong et al., 2010; Pan et al., 2014a)
184Mesendanin FTwigs and leavesM. toosendanDong et al. (2010)
185Toosendansin GFruitsM. toosendanLi et al. (2020b)
186Meliatoosenin RFruitsM. toosendanZhang et al. (2012)
Meliacarpinin class
187Toosendane ABarksM. toosendanHu et al. (2018)
188Toosendane BBarksM. toosendanHu et al. (2018)
189Toosendane CBarksM. toosendanHu et al. (2018)
1903,20-Diacetyl-11-methoxymeliacarpininBarksM. toosendanHu et al. (2018)
1913,20-Diacetyl-1-tigloyl-11-methoxymeliacarpininBarksM. toosendanHu et al. (2018)
192Meliacarpinin ARoot barksM. toosendanNakatani (1999)
193Meliacarpinin CRoot barksM. toosendanNakatani (1999)
194Meliacarpinin DRoot barksM. toosendanNakatani (1999)
195Meliacarpinin ERoot barksM. azedarachHuang et al. (1996)
1961-Deoxy-3-tigloyl-11-methoxymeliacarpininBarksM. azedarachHuang et al. (1994)
1973α-(2-Methylbutyryl)-1,20-diacetyl-11-methoxymeliacarpininTwigs and leavesM. azedarachZhang et al. (2014)
1983-Tigloyl-1,20-diacetyl-11-methoxymeliacarpininTwigs and leavesM. azedarachZhang et al. (2014)
1991-Methacrylyl-3-acetyl-11-methoxymeliacarpininRootsM. azedarachNakatani (1999)
2001-(2-Methylpropanoyl)-3-acetyl-11-methoxymeliacarpininRootsM. azedarachNakatani (1999)
2011-Cinnamoyl-3-hydroxy- 11-methoxymeliacarpininBarksM. azedarachTakeya et al. (1996a)
2021-Deoxy-3-methacrylyl-11-methoxymeliacarpininBarksM. azedarachTakeya et al. (1996a)
Meliacarpin class
2031,3-Dicinnamoyl-11-hydroxymeliacarpinLeavesM. azedarachBohnenstengel et al. (1999)
2041-Cinnamoyl-3-methacrylyl-11-hydroxymeliacarpinLeavesM. azedarachBohnenstengel et al. (1999)
2051-Cinnamoyl-3-acetyl-11-hydroxymeliacarpinLeavesM. azedarachBohnenstengel et al. (1999)
2061-Cinnamoyl-3-feruloyl-11-hydroxymeliacarpinLeavesM. azedarachBohnenstengel et al. (1999)
207AzadirachtinLeavesM. azedarachBohnenstengel et al. (1999)
2081-Cinnamoyl-3,11-dihydroxymeliacarpinLeavesM. azedarachBarquero et al. (2006)
Others
209Meliatoosenin SFruitsM. toosendanZhang et al. (2012)
210SpirosendanRoot barksM. toosendanNakatani et al. (1999)
211VolkensininBarksM. volkensiiRogers et al. (1998b)
212Azecin 1RootsM. azedarachTan and Luo (2011)
213Azecin 3RootsM. azedarachTan and Luo (2011)
214Azecin 4RootsM. azedarachTan and Luo (2011)

Classifications and sources of limonoids isolated from genus Melia.

Trichilin Class (1–67)

The basic skeleton of the trichilin class limonoids contained the C-19/29 bridged acetal and the 14,15-epoxide moieties or C15 carbonyl. Toosendanin, as a characteristic compound in trichilin class, has been confirmed to be a potential bioactive component in the field of anti-tumor, insecticide, and anti-botulism. It should be noted that toosendanin can only be isolated from two plant species, M. toosendan and M. azedarach (Shi and Li, 2007). The first isolation and identification of toosendanin can be traced back to 1975. In 1980, Chinese researchers corrected its chemical structure due to the occurrence of two tautomers found by paper chromatography and silica gel plate method (Su and Liang, 1980). In 1984, iso-toosendanin, the isomer of toosendanin, was also isolated from these two plants. In 1998, Zhou et al. isolated four new trichilin class limonoids from the root barks of M. toosendan, of which neoazedarachin D was found to be the first natural 29-endo-derivative in C (19)/C (29) bridged acetal limonoids (Zhou et al., 1998). Apart from C-19/29 bridged acetal, toosendanal with C (1)/C (29) bridged acetal was also discovered in M. toosendan (Tada et al., 1999) (Figure 2).

FIGURE 2

FIGURE 2

Structures of trichilin class limonoids 1–67.

Vilasinin Class (68–82)

6α,28-ether bridge was supposed to be a typical skeleton of vilasinin class limonoids. Trichilinin B, C, D, and E, four new limonoids with 6α,28-ether bridge, were isolated and identified from the root barks of M. toosendan. It was found that the unique C-12 oxygen function in trichilinin B, C, and E seemed to be the biosynthetic precursors of ring-C-cleaved limonoids (Nakatani, 1999). Using activity-guided separation, meliavolkin was isolated from M. volkensii Gürke., and its structure was elucidated by MS, 1H and 13C NMR, COSY, NOESY, HETCOR, and COLOC spectra (Zeng et al., 1995a) (Figure 3A).

FIGURE 3

FIGURE 3

Structures of vilasinin class limonoids 68–82 (A), structures of havanensin class limonoids 83–96 (B), and structures of azadirone class limonoids 97––99 (C).

Havanensin Class (83–96)

The havanensin class limonoids were characteristic of C-1, C-3, and C-7 oxygen substituents, and C-28 will be oxidized, which varies from methyl to carboxyl. In 1998, melianin C was isolated from M. volkensii Gürke., which was confirmed to have a consistent structure with the semisynthetic compound obtained by Jones oxidation of melianin A, and it was also the first report that melianin C appeared naturally (Rogers LL. et al., 1998). Sendanal was associated closely with a precursor of the 14,15-epoxy-12-hydroxymoiety, which could produce the ring-seco limonoids through a Grob fragmentation followed by the formation of an ether ring between the C-7 and C-15 hydroxyl groups via an SN1 mechanism (Tan and Luo, 2011) (Figure 3B).

Azadirone Class (97–99)

The 3-oxo-Δ1,2 and C-7 oxygenation was considered as a vital feature of azadirone-type limonoids. The first isolation of azadirone can be traced back to 1998, and it was firstly isolated from the root barks of M. toosendan, together with acetyltrichilenone (Nakatani, 1999) (Figure 3C).

Ring-Seco Limonoids (100–208)

The ring-C-seco limonoids have the most typical chemical structure of all ring-seco limonoids. According to different structural characteristics, the ring C-seco limonoids can be classified into nimbolinin class, ohchinolide class, nimbolidin class, salannin class, ohchinolal class, meliacarpinin class, and meliacarpin class (Figures 46).

FIGURE 4

FIGURE 4

Structures of nimbolinin class limonoids 100–133 (A), structures of ohchinolide class limonoids 134–142 (B), and structures of nimbolidin class limonoids 143–150 (C).

FIGURE 5

FIGURE 5

Structures of salannin class limonoids 151–177 (A), structures of ohchinolal class limonoids 178–186 (B), and structures of meliacarpinin class limonoids 187–202 (C).

FIGURE 6

FIGURE 6

Structures of meliacarpin class limonoids 203–208 (A) and structures of other-class limonoids 209–214 (B). Rha, rhamnose; Glc, clucose; Ara, arabinose.

FIGURE 7

FIGURE 7

Abbreviation of structure.

Synthesis of Limonoids

Due to the remarkable pharmacological activities and the unique structural features, many endeavors have been devoted to the synthesis of limonoids found in the genus Melia. Inspired by the anti-botulinum effect and structural diversity of toosendanin, researchers have conducted a synthesis or structural modification of this chemical structure. Excitedly, a similar framework can be found in all mammalian steroids and hormones. Although total synthesis seems like an ideal synthesis approach, the complexity of structure and uncertainty of total synthesis make researchers choose function-oriented synthesis (FOS) as an alternative. FOS aims to emulate a bioactive lead structure or possibly substitute for it with simpler scaffolds designed to contain the active chemical structure sites of target compounds (Wender, 2013). Considering that there were no previous reports on bioactive structural features, Nakai et al. cleaved toosendanin into AB and CD rings, and the biological activity of CD rings was probed by mouse lethality assay, which was deemed to be a “gold standard” in the validation of anti-botulinum activity. Using mesityl oxide and acetylacetone as synthetic substrates, a 4-acetoxy CD fragment analogue of toosendanin was synthesized in 14 steps. Unluckily, no significant anti-botulinum effect was found in the obtained 4-acetoxy CD fragment. Nevertheless, this synthetic method can provide certain inspiration for synthesizing the CD ring analogues (Nakai et al., 2009). Later, in 2010, Nakai et al. focused on AB ring synthesis, which contained a unique bridged hemiacetal, and the anti-botulinum effect was tested in a rat spinal cord cellular assay. The AB ring and epi-AB ring were successfully synthesized with a yield rate of 5.8 and 10% after 23 steps and 19 steps, respectively. Similar to the previously synthesized CD ring, the AB ring did not exhibit anti-botulism activity. All of these results indicated that the complete structure of the ABCD ring is indispensable in the treatment of botulism (Nakai et al., 2010). Apart from exploring the influence of ring structure on the bioactivity of toosendanin, the role of substituents at different positions was investigated as well. By modifying the C-28 position of toosendanin, 12 28-acyloxy derivatives were semi-synthesized, and the insecticidal activity against Mythimna separata Walker was evaluated. The outcomes revealed that the butanoyloxy and phenyl acryloyl oxymoiety at the 28-position plays a critical role in insecticidal activity (Xu and Zhang, 2011) (Figure8). Except for the organic synthesis mentioned above, the biosynthesis of toosendanin also aroused great attention. Since the cyclization of 2,3-oxidosqualene by oxidosqualene cyclase (OSC) is the first stage of triterpenoid biosynthesis to produce diverse triterpene frameworks, Lian et al. found potential OSC genes in M. toosendan by utilizing the triterpenoid profile, transcriptome data, and phylogenetic analysis. The following functional analysis discovered that MtOSC1 was a crucial enzyme in the formation of tirucalla-7,24-dien-3β-ol, which is a precursor for the biosynthesis of toosendanin (Lian et al., 2020). This study revealed that the practicable biosynthesis route of toosendanin may promote its application both in agricultural and medicinal use. Furthermore, salannin and 3-deacetylsalannin can be transformed into 3-deacetoxy-1-de[(E)-2-methylbut-2-enoloxy]salannin-1-en-3-one by Nocardia sp., and the transformed product was validated as a candidate bioactive compound with an α,β-unsaturated ketone moiety in ring A (Madyastha and Venkatakrishnan, 2000).

FIGURE 8

FIGURE 8

The synthetic route of 28-acyloxy derivatives of toosendanin.

Biological Activities of Limonoids

Anti-tumor Effects

Accumulating studies have found that limonoids possessed broad-spectrum anti-tumor activities against multiple tumors, such as gastric tumor (Shao et al., 2020), lung tumor (Luo et al., 2018), colorectal tumor (Wang et al., 2015), glioblastoma (Cao et al., 2016), leukemia (Ju et al., 2012), ovarian tumor (Li et al., 2018b), hepatocellular carcinoma (He et al., 2010), breast tumor (Wang et al., 2018), Ewing’s sarcoma (Gao et al., 2019), neuroma (Tang et al., 2004), lymphoma (Zhang B. et al., 2005), and pancreatic tumor (Pei et al., 2017), which indicated that limonoids could be candidate anticancer drugs. Toosendanin (TSN), as a quality control marker in M. toosendan and M. azedarach, has been systematically investigated for its anti-tumor effects. Thus, this review primarily focused on summarizing the anti-tumor activity of TSN and its underlying mechanisms, including the inhibition of tumor cell proliferation, induction of apoptosis, suppression of migration, and invasion. Besides these, we also comprehensively reviewed the anti-tumor bioactivities of other limonoids in genus Melia plants.

Effect of Toosendanin on Tumor Cell Proliferation and Cell Cycle Arrest

Tumor cell proliferation is the basis of tumor growth and metastasis. Inhibition of tumor cell proliferation has been considered as one of the pivotal anti-tumor therapies (Whitfield et al., 2006). It was found that TSN could inhibit the proliferation of MKN-45 gastric cancer cells in a time-dependent and dose-dependent manner, and the IC50 value was 81.06 nM for 48 h (Shao et al., 2020). In addition, some other experiments showed that TSN was able to restrain the proliferation of various cancer cell lines, including SGC-7901 cells (Wang et al., 2017), MGC-803 cells, and HGC-27 cells with IC50 values of 0.11 μM (72 h), 20.30 nM (72 h), and 0.56 µM (48 h), respectively. Using the MTT method, Liu et al. reported that the proliferation of lung cancer A549 cells could be inhibited by TSN with an IC50 value of 40.206 μM for 48 h. Meanwhile, the same inhibitory effect was found in H1975 lung cancer cells. When treating colorectal cancer SW480 cells with TSN, it exhibited anti-proliferation effects with an IC50 value of 0.1059 µM (48 h) (Wang et al., 2015). In order to further explore the anti-tumor effect of TSN in colorectal cancer, a nude mouse xenograft model was established, which subcutaneously inoculated HCT116 cells into nude mice. The outcomes indicated that TSN significantly reduced the tumor volume and weight of the HCT116 xenografts (Wang et al., 2020b). Apart from cancer mentioned above, TSN was found to possess anti-proliferation effects on some other types of tumor, such as glioblastoma, leukemia, ovarian cancer, hepatocellular carcinoma, etc., with IC50 values ranging from 5.4 to 900 nM (Zhang B. et al., 2005; He et al., 2010; Cao et al., 2016; Gao et al., 2019).

The proliferation of tumor cells needs to go through four different stages: pre-DNA synthesis (G1), DNA synthesis (S), late DNA synthesis (G2), and mitosis (M). Since the aberrant activity of various cyclins can lead to the uncontrolled proliferation of tumor cells, treating aberrant cyclins was thus considered as an attractive target for tumor therapy (Otto and Sicinski, 2017). Shao et al. found that TSN-treated MKN-45 human gastric cancer cells markedly arrested at the G1 phase, which was regulated by the overexpression of mir-23a-3p (Shao et al., 2020). In another study, researchers showed that treatment with TSN at concentrations of 2 and 5 μM can cause G1/S arrest in AGS and HGC-27 gastric cancer cells. For a further evaluation of cell cycle arrest, the expression of G1 checkpoint-associated proteins, including cyclin D1 and p21, was assessed. It was observed that TSN treatment could decrease the expression of cyclin D1, while it could increase the expression of p21 (Zhou et al., 2018). Furthermore, in both 5-FU-sensitive and 5-FU-resistant colorectal cancer cells, G1 phase arrest could be induced by TSN. The results also found that, apart from decreased cyclin D1 and increased p21, the expression of p53, a G1-phase checkpoint-associated protein, increased as well (Wang et al., 2020b). In addition, cell cycle arrest also occurred in other tumor cells, such as glioblastoma (Wang Q. et al., 2020) and leukemia (Ju et al., 2013).

Effect of Toosendanin on Tumor Cell Apoptosis

Concerning the anti-tumor effects of TSN, much work has focused on cell apoptosis. Inducing tumor cell apoptosis is now generally considered as the most important mechanism of anti-tumor drugs. Apoptosis, also known as programmed cell death, is a kind of cell-autonomous and orderly death mode, which is activated, expressed, and regulated by specific genes in cells (Li-Weber, 2013). TSN was recently regarded as a potential candidate that killed tumor cells through the induction of apoptosis in various cancer cells, including gastric cancer (Wang et al., 2017; Zhou et al., 2018; Shao et al., 2020), lung cancer (Wang et al., 2017), colorectal cancer (Wang et al., 2015; Wang et al., 2020b), glioblastoma (Cao et al., 2016; Wang Q. et al., 2020), leukemia (Ju et al., 2012; Ju et al., 2013), ovarian cancer (Li et al., 2018a; Li et al., 2019), hepatocellular carcinoma (He et al., 2010; Liu et al., 2016), breast cancer (Wang et al., 2018), Ewing’s sarcoma (Gao et al., 2019), neuroma (Tang et al., 2004), and lymphoma (Zhang B. et al., 2005). Herein our study summed up the detailed mechanisms of apoptosis induced by TSN (Figure 9).

FIGURE 9

FIGURE 9

Targeting the apoptosis signaling pathways by toosendanin in cancers.

Targeting the Intrinsic Pathway

The intrinsic pathway is also known as cell mitochondrial apoptosis. When cells are exposed to various stimulating factors, such as hypoxia, activation of the oncogene, DNA damage, and cytotrophic factor deficiency, the steady state of mitochondrial membrane potential will be destroyed, and the permeability can increase. Subsequently, the pro-apoptotic factors in the mitochondrial membrane are released to the cytoplasm, which later activates the apoptosis pathway of the mitochondria and causes cell death (Estaquier et al., 2012). Cytochrome c (Cyt C), apoptosis-inducing factor, cysteinyl aspartate-specific proteinase (caspase) activator, and apoptotic protease-activating factor-1 (Apaf-1) are supposed to be pivotal pro-apoptotic factors. The apoptosome complex is formed by the combination of released Cyt C with Apaf-1 and caspase-9, which activates caspase-3 and eventually induces apoptosis. Importantly, regulating the B-cell lymphoma-2 (Bcl-2) protein family has been considered as an essential route to play a role in cell mitochondrial apoptosis signal pathway, the mechanism of which is to control the permeability of the mitochondrial membrane to regulate the release of Cyt C (Siddiqui et al., 2015).

Collectively, TSN-induced apoptosis of tumor cells is related to the activation of the intrinsic pathway. On the one hand, the capacity of cells to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the Bcl-2 protein family. According to the difference of its functional domain, it can be divided into anti-apoptotic Bcl-2 subfamily (e.g., Bcl-2, Bcl-xL, and Mcl-1), pro-apoptotic Bax subfamily (e.g., Bax and Bak), and BH3-only pro-apoptotic family (e.g., Bid, Bim, Bik, and Noxa) (Campbell and Tait, 2018). On the other hand, the caspase family is known as the most well-studied apoptotic executive protein, which has the characteristics of post-aspartic protein hydrolysis. Based on their different roles in apoptosis, it can be classified into two types: the initiator (apical) caspases (e.g., caspase-2, -8, -9, and -10) and effector (executioner) caspases (e.g., caspase-3, -6, and -7) (Ola et al., 2011). The caspase family implements its pro-apoptotic effect mainly through the combination of apoptosis signal and death receptor to induce the activation process of initiator and effector caspase protein and the subsequent inactivation process of apoptosis-inhibitory protein and cause nucleic acid and cell structure cleavage and so on (Fiandalo and Kyprianou, 2012). When administrated with TSN, several typical characteristics of apoptosis occurred, including nuclei condensation, DNA fragmentation, reduction of mitochondrial membrane potential, and the upregulation of cytochrome c in cytosol (Tang et al., 2004; Shao et al., 2020). Subsequently, caspase 9 and caspase 3 were activated (Tang et al., 2004; He et al., 2010; Ju et al., 2013; Zhou et al., 2018; Gao et al., 2019; Wang et al., 2020b; Shao et al., 2020), and TSN promoted poly-ADP-ribose polymerase (a target protein of caspase 3) fragmentation (Tang et al., 2004; Ju et al., 2013; Zhou et al., 2018; Wang et al., 2020b), eventually leading to apoptosis. Some other researches showed that TSN treatment significantly increased the pro-apoptotic protein expression of Bax (He et al., 2010; Ju et al., 2013; Cao et al., 2016; Liu et al., 2016; Zhou et al., 2018; Gao et al., 2019; Shao et al., 2020), Bak (Cao et al., 2016), Bim, and Noxa Apaf-1 (Shao et al., 2020) and decreased the anti-apoptotic protein expression of Bcl-2 (He et al., 2010; Ju et al., 2013; Cao et al., 2016; Liu et al., 2016; Wang et al., 2017; Zhou et al., 2018; Gao et al., 2019; Wang et al., 2020b; Shao et al., 2020), Bcl-xL (Zhou et al., 2018; Wang et al., 2020b), Mcl-1 (Zhou et al., 2018; Wang et al., 2020b), and XIAP (Zhou et al., 2018; Wang et al., 2020b), thus inducing apoptosis-associated caspase activation.

Targeting the Extrinsic Pathway

The death receptor (DR)-mediated apoptosis signaling pathway is a kind of a signal pathway that interacts with proteins mediated by transmembrane receptors. Death receptors belong to the tumor necrosis factor receptor (TNFR) superfamily, including Fas (also known as CD95 or Apo-1), TNFR-1, TNFR-2, DR3, DR4, and DR5 (Tummers and Green, 2017). Up to now, the Fas/FasL signaling pathway is considered as the most crucial signaling pathway in death receptor-mediated apoptosis. The corresponding mechanism is as follows: FAS is activated after binding with FasL. The activated Fas receptor recruits Fas-associated death domain protein (FADD) through the interaction of death domain (DD). FADD can not only bind Fas through DD at the C-terminal but also recruit procaspase-8 through N-terminal death effector domain and finally form Fas receptor–FADD–procaspase-8 death-inducing signaling complex (DISC). With the increase of the local concentration of DISC, procaspase-8 can catalyze the formation of active caspase-8 in DISC and then activate the downstream caspase factor, thus initiating the apoptosis process dependent on caspase cascade reaction (Wajant, 2002; Singh et al., 2016). Integral in the regulation and initiation of death receptor-mediated activation of programmed cell death is caspase-8 (Tummers and Green, 2017). To escape exogenous apoptosis, cancer cells often downregulate the expression of death receptors by using antagonistic machinery (Friesen et al., 1997). Therefore, recovering Fas expression by drug intervention is anticipated to trigger cancer cell apoptosis.

It was observed that TSN could induce apoptosis by increasing the expression of Fas to inhibit hepatocellular carcinoma cells (He et al., 2010; Liu et al., 2016). In addition, for the ovarian cancer CAOV-3 and ES-2 cells, when treated with TSN, the expression of Fas and FasL increased firstly, subsequently followed by the activation of caspase-8 and caspase-3. After the administration of z-IETD-FMK and z-DEVE-FMK (the inhibitors of caspase-8 and caspase-3, respectively), the inhibitory effect of TSN on the proliferation of these cancer cells was reduced (Li et al., 2019). The increased expression of Fas, caspase-8, and caspase-3 was also exhibited in leukemia K562 cells after incubation with TSN. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent that belongs to the TNF superfamily (Ashkenazi et al., 1999). Many cancer cells remain resistant to receptor-mediated apoptosis—for instance, the TRAIL-mediated apoptotic resistance appears in non-small-cell lung carcinoma, and the TSN showed a sensitivity-enhanced ability for cancer cell apoptosis. The underlying apoptotic mechanisms involved the upregulation of death receptor 5 (DR5) mediated by CCAAT/enhancer binding protein homologous protein (Li et al., 2017). Consistently, the upregulated expression of DR5 was found in TRAIL inhibiting hepatocellular carcinoma.

Other Mechanisms of Apoptosis

Recently, intracellular calcium ion (Ca2+) has been regarded to play a vital role in cell apoptosis, and Ca2+ overload was considered as the common final pathway of all types of cell death (Rizzuto et al., 2003). Ca2+ can induce apoptosis through regulating apoptosis-related molecules, producing reactive oxygen species (ROS), and changing cell membrane permeability (Orrenius et al., 2003). Shi et al. reported that TSN had an inhibitory effect on neuroblastoma glioma NG108-15 cells. Since TSN cannot penetrate the lipid bilayer, it was found that TSN exerted the anti-cancer role by facilitating the Ca2+ channel of the cell membrane (Hu et al., 1997). In order to further confirm which Ca2+ channel was regulated by TSN, a series of physiological experiments was carried out. These findings showed that TSN could facilitate the L-type Ca2+ channel in the cell membrane, thus promoting extracellular Ca2+ influx. In addition, intracellular Ca2+ overload can directly induce apoptosis (Li and Shi, 2004). It was reported that TSN, at different concentrations, could cause different changes to the PC12 cells, and these distinctions were closely related with the increase of [Ca2+]i, which indicated that Ca2+ played an essential role in cell apoptosis (Li and Shi, 2005).

Moreover, TSN can trigger some different pathways to induce cancer cell apoptosis. In one study, TSN was proven as a candidate of novel anti-cancer drugs for glioblastoma, and the underlying mechanism was inducing estrogen receptor β- and p53-mediated apoptosis (Cao et al., 2016). In addition, the c-Jun N-terminal kinase (JNK) signaling pathway was also involved in TSN-induced apoptosis. In a representative study, TSN was found to induce apoptosis by suppressing the CDC42/MEKK1/JNK pathway in human promyelocytic leukemia HL-60 cells (Ju et al., 2013). Furthermore, the PI3K–Akt signaling pathway acted a crucial role in apoptosis, and excessive activation of PI3K/Akt signaling in cancer cells was involved in the development of multidrug resistance (Burris, 2013). It was observed that TSN could reverse the resistance of human breast cancer cells 4T1 to adriamycin by inhibiting the PI3K/Akt signaling pathway (Wang et al., 2018). Recently, the role of microRNAs (miRNAs) in the treatment of cancer by TSN was explored. The outcomes showed that TSN could inhibit glioma progression property and induce apoptosis via upregulating the expression of miR-608 and downregulating the expression of miR-608 targets, Notch1 and Notch2, in glioma (Wang Q. et al., 2020).

Effect of Toosendanin on Tumor Invasion and Metastasis

About 90% of cancer-related deaths are associated with metastatic diseases rather than primary tumors (Jafri et al., 2017). Emerging evidence showed that TSN could inhibit cancer invasion and metastasis (Pei et al., 2017; Wang et al., 2017; Luo et al., 2018; Wang Q. et al., 2020). The migration and invasion of tumor cells is a complex process of multiple factors, stages, and steps. It involves the process of epithelial–mesenchymal transition (EMT), the degradation of basement membrane and extracellular matrix, the decrease of tumor cell adhesion, and angiogenesis. Among these pathological processes, EMT acts a pivotal role, and its function is transforming the polarized epithelial cell into the mesenchymal cell phenotype. E-cadherin is a marker of epithelial cells, which maintains the integrity of tissue structure by regulating the adhesion reaction between cells and matrix or between cells. Mesenchymal proteins such as N-cadherin and vimentin are highly expressed with the decrease of E-cadherin expression, which collaboratively induces the EMT process (Sachdeva and Mo, 2010). In the transforming growth factor-β1 (TGF-β1)-induced EMT cell model, the inhibitory effect of TSN on A549 and H1975 lung cancer cell migration, invasion, and adhesion was evaluated by wound healing, transwell, and adhesion assays. The outcomes indicated that TSN could weaken the abilities mentioned above, decrease the expression of N-cadherin, vimentin, and p-ERK1/2, and increase the expression of E-cadherin. Besides these, TGF-β1-induced EMT biomarkers can be reversed by silence Snail. These results demonstrated that TSN significantly inhibited TGF-β1-induced EMT and migration, invasion, and adhesion through the ERK/Snail pathway in lung cancer cells (Luo et al., 2018). Consistently, in CAVO-3 human ovarian cancer cells, invasion and migration could be inhibited by TSN, followed by increased NF-κB and E-cadherin and decreased N-cadherin, vimentin, and Snail. The underlying mechanism may be related with the NF-κB/Snail pathway (Li et al., 2018b). Recently, the β-catenin pathway has been considered as the crucial signaling pathway involved in EMT and plays an important role in metastasis. TSN was confirmed to inhibit migration, invasion, and TGF-β1-induced EMT via miR-200a-mediated downregulation of the β-catenin pathway in SGC-7901 human gastric carcinoma cells (Wang et al., 2017). Furthermore, TGF-β1-induced EMT and morphological change in pancreatic cancer cells can be reversed through upregulating E-cadherin expression and decreasing vimentin, ZEB1, and Snail levels. The corresponding mechanism was involved with blocking the Akt/mTOR signaling pathway (Pei et al., 2017).

Synergistic Effect of Toosendanin in Chemotherapy

Since the majority of chemotherapy drugs have serious side effects, it is still urgent to take adjuvant therapy to reduce the dosage of chemotherapy drugs and improve their anti-tumor activity. As a representative chemotherapy drug, cisplatin is used to treat non-small cell lung cancer (NSCLC), but due to the development of resistance, the benefit has been limited. It was found that TSN can enhance cisplatin sensitization against non-small cell lung cancer cells through targeting Anxa4 in NSCLC cells, decreasing the combination of Anxa4 with ATP7A, and decreasing the extracellular efflux of platinum. The results showed that TSN could be a potential candidate in treating drug-resistant NSCLC cells (Zheng et al., 2018). Adriamycin (ADM) is an anti-cancer drug with a high frequency of use in the treatment of breast cancer. Nevertheless, some kinds of breast cancer or breast cancers under repeated ADM exposure develop a strong resistance to ADM, which limits its clinical efficacy. Wang et al. found that TSN can attenuate the resistance of human breast cancer cells to ADM by inhibiting the expression of ABCB1 and PI3K/Akt signaling (Wang et al., 2018). Doxorubicin, another anti-cancer antibiotic, possesses a strong anti-tumor effect. However, the toxicity of high-dose doxorubicin is severe, especially to the heart. In MDA-MB-435 breast cancer cells, cotreatment of doxorubicin with TSN can significantly enhance the anti-breast cancer activity, and the mechanism may depend on the FoxO1-Bim/Noxa pathway.

Selective Inhibition Effect of Toosendanin on Tumor Cells

The specific inhibitory effect on tumors is crucial for the development of new anti-tumor drugs. In one study, Li et al. showed that TSN selectively increased the sensitivity of NSCLC cells, but not normal cells (293T, BEAS-2B, HBE, L02, and PBMC), to TRAIL-induced apoptosis (Li et al., 2017). For the toxicity of hepatocellular carcinoma, after treating with toosendanin (0.5 µM) for 72 h, the inhibition rate for SMMC-7721 and Hep3B cells was 56 and 42%, respectively, and for IAR-20 and L02 cells (normal liver cell lines), it was 21 and 20%, respectively (He et al., 2010). When treated with a lower dosage range (0.25–1 µM), toosendanin could selectively kill human gastric carcinoma cells (MGC-803, BGC-823, HGC-27, AGS, SGC-7901, and MKN-45) rather than normal human gastric epithelial cells (GES-1) (Wang et al., 2017). The selective inhibition effect of toosendanin against tumor cells was cross-validated in different research groups. According to the results of Yan and Zhang, the IC50 of toosendanin on normal primary hepatocyte cells was 30.65 and 14.94 μM, respectively, which was higher than its suppressing effect on hepatocellular carcinoma (0.5–0.9 μM) as reported by other teams (Zhang et al., 2008; He et al., 2010; Liu et al., 2016; Yan et al., 2019).

Anti-tumor Effects of Other Limonoids

Inspired by the remarkable bioactivity, numerous works have been conducted to isolate and identify the potential lead compounds from genus Melia plants for cancer treatment. Three limonoids, including trichilinin B, 3-deacetyl-4′-demethyl-28-oxosalannin, and 23-hydroxyohchininolide, were cytotoxic to gastric cancer cell line of AZ521 with IC50 values of 58.2, 3.2, and 78.5 µM, respectively (Pan et al., 2014b). In another study, 31 limonoids were isolated and identified from the fruits of M. azedarach; among them, several compounds including meliarachin C, 12-dehydroneoazedarachin D, salannin, 1-O-decinnamoyl-1-O-benzoylohchinin, ohchininolide, 1-O-decinnamoyl-1-O-benzoylohchininolide, 23-hydroxyohchininolide, 1-O-decinnamoyl-1-O-benzoyl-23-hydroxyohchininolide,1-O-decinnamoyl-1-O-benzoyl-28-oxoohchinin, mesendanin E, 1-benzoyl-1-detigloylohchinolal, and nimbolinin D possessed anti-tumor effect against AZ521 cells, and 12-dehydroneoazedarachin D showed the most potent cytotoxicity with an IC50 value of 11.8 µM (Akihisa et al., 2013). In addition, trichilinin E exhibited apparent cytotoxicity against the gastric cancer cell line SGC-7901 (Zhou et al., 2016).

For lung cancer treatment, 12-hydroxyamoorastatone, 12-hydroxyamoorastatin, 12-acetoxyamoorastatin, meliarachin C, 1-O-decinnamoyl-1-O-benzoylohchinin, 1-O-decinnamoyl-1-O-benzoyl-23-hydroxyohchininolide, and 1-benzoyl-1-detigloylohchinolal were reported to be toxic against A549 cell, and 1,12-diacetyltrichilin B showed significant cytotoxicity with an IC50 value of 0.93 µM (Tada et al., 1999; Zhao et al., 2012; Akihisa et al., 2013). The isolated limonoids can also inhibit colorectal cancers. Among them, 12-hydroxyamoorastatone, 12-hydroxyamoorastatin, and 12-acetoxyamoorastatin displayed obvious antitumor activity against HCT-15 cell. Notably, 12-acetoxyamoorastatin possessed stronger cytotoxicity than antimycin A (positive drug), which indicated that it could be a candidate in curing colorectal cancer (Ahn et al., 1994). The anti-tumor effect was also found in SW480 colorectal cancer cells by 1,12-diacetyltrichilin B (Yuan et al., 2013). It was reported that lots of limonoids have a cytotoxic effect on leukemia HL-60 cells. Among them, 3-deacetyl-4′-demethyl-28-oxosalannin, 1,12-diacetyltrichilin B, meliarachin C, 1-O-cinnamoyltrichilinin, 23-methoxyohchininolide A, 1-benzoyl-1-detigloylohchinolal, 1-cinnamoyl-1-detigloylohchinolal, and nimbolinin D were considered as the most potential compounds with an IC50 value lower than 10 µM (Zhao et al., 2012; Akihisa et al., 2013; Pan et al., 2014b). Simultaneously, 12 limonoids from the fruits of M. azedarach also possessed marked anti-tumor activity against breast cancer MCF-7 cell with IC50 values from 0.06 to 94.8 µM (Akihisa et al., 2013). Toosendansin H, meliatoxin B1, and 1,12-diacetyltrichilin B, which were isolated from the fruits and stem bark of M. toosendan, were toxic to MCF-7 cell (Zhao et al., 2012; Li et al., 2020b). Moreover, trichilinin B and 21-hydroxyisoohchininolide can inhibit the growth of SK-BR-3 cell, which is another type of breast cancer cell (Pan et al., 2014b).

MTT assay was applied to evaluate the cytotoxicity of nine limonoids against lymphoma P388 cell. The outcomes revealed that all the nine limonoids possessed apparent toxicity, of which 12-deacetyltrichilin I, 3-deacetyltrichilin H, and trichilin D exhibited significant bioactivity with IC50 values of 0.011, 0.045, and 0.055 μg/ml, respectively (Takeya et al., 1996b). In the treatment of oral epithelial carcinoma, trichilin H (IC50 = 0.11 μg/ml) and 12-O-methylvolkensin (IC50 = 8.72 μg/ml) were observed to be toxic to kB cells (Tada et al., 1999). Zhou et al. isolated three new C-seco limonoids and one new tetracyclic limonoid from the fruits of M. azedarach, and their cytotoxicity against cervical cancer HeLa S3 cells was assessed. The results showed that 15-O-deacetylnimbolidin B and 12-O-deacetyltrichilin H had a strong inhibitory effect, while 15-O-deacetyl-15-O-methylnimbolidin A and 15-O-deacetyl-15-O-methylnimbolidin B had weak cytotoxicity (Zhou et al., 2005). Furthermore, using bioassay-guided chemical investigation, 12-hydroxyamoorastatone, 12-hydroxyamoorastatin, and 12-acetoxyamoorastatin were isolated, and the anti-tumor effects were evaluated. Three compounds showed potent cytotoxicity against human malignant melanoma SK-MEL-2 and human CNS carcinoma XF498 (Ahn et al., 1994). Several limonoids also possessed noticeable hepatotoxicity. Among them, 12-ethoxynimbolinins G and 1,12-diacetyltrichilin B were toxic to SMMC-7721 cells, with IC50 values of 27.6 and 0.36 µM, respectively, and trichilinin E had cytotoxicity against HepG2 cell (Yuan et al., 2013; Zhou et al., 2016; Zhang et al., 2018).

Structure–Activity Relationships With Anti-tumor

In order to further explain the effect of different skeletons and substituents on the anti-tumor activities of limonoids, the corresponding structure–activity relationships (SAR) were systematically summarized. For trichilin-type limonoids, it was found that meliarachin C and toosendanin with a β-oriented epoxy ring at C-14/C-15 possessed a significant bioactivity than those of their 15-oxo analogues (meliarachin K and meliarachin G) against HL60 and AZ521 cells. Meanwhile, the inhibitory effect of 15-oxo trichilins against HL60 and AZ521 cells could be enhanced by deacetoxylation at C-12 (12-dehydroneoazedarachin D vs. meliarachin K). For vilasanin-type limonoids, acetylation of the hydroxy group at C-3 was able to strengthen the anti-cancer effect against HL60 cells—for instance, 1-O-cinnamoyltrichilinin (IC50 = 5.8 μM) vs. trichilinin D (IC50 = 61.2 μM). This structural modification also enhanced the activity against HL60 cells in the salannin-type limonoids with a cinnamoyl group at C-1 (ohchinin acetate vs. ohchinin). By contrast, acetylation at C-3 could reduce the bioactivity of salannin-type limonoids, which bore a tigloyl group at C-1 (salannin vs. 3-O-deacetylsalannin). In addition, the substitution of a methacrylic group at C-1 with a benzoyl group reduced the activity against HL60 and AZ521 cells (3-deacetyl-4′-demethyl-28-oxosalannin vs. 1-O-decinnamoyl-1-O-benzoyl-28-oxoohchinin). The characteristic SAR was also found in ohchinolal-type limonoids. The study showed that the inhibitory properties against HL60 cells would be reduced when the cinnamoyl group at C-1 was substituted by a methacrylic or a tigloyl group (1-cinnamoyl-1-detigloylohchinolal vs. mesendanin E and ohchinolal) (Akihisa et al., 2013). Surprisingly, the demethacrylation of mesendanin E and the detigloylation of ohchinolal at C-1 were able to enhance the anti-cancer ability against HL60, A549, and AZ521 cells. This finding indicated that substitution of methacrylic or tigloyl group at C-1 was probably related with anti-cancer property (Pan et al., 2014a) (Figures 10).

FIGURE 10

FIGURE 10

The anti-tumor structure–activity relationship of limonoids.

FIGURE 10

FIGURE 10

(continue) The anti-tumor structure—activity relationship of limonoids.

Antifeeding and Insecticide Effects

Antifeeding and Insecticide Effects of Toosendanin

M. toosendan and M. azedarach, two common agricultural insecticidal and Ascaris-repellent Chinese herbs, have been recorded in ancient China, and TSN has been considered as the main active compound for insecticidal effect. The content of TSN in M. toosendan is high, and it is environmentally friendly due to its botanical property (Shi and Li, 2007). Recently, TSN showed distinguished potential in the field of agricultural anthelmintic. It was reported that TSN possessed remarkable repellent and insecticidal effects on Pieris rapae, and the underlying mechanism has been explored comprehensively. TSN also has obvious antifeedant activity. TSN at different dosages can affect the feeding reaction and feeding speed of P. rapae, which exhibited different poisoning symptoms. A high dose of TSN can induce the paralysis and coma of P. rapae and cause pathological changes of the midgut. Meanwhile, a low dose of TSN can transform the larvae into abnormal insects. One study was designed to evaluate the effects of TSN on the activities of several important enzymes in P. rapae. The results showed that TSN was able to reduce the activities of microsomal multifunctional oxidase, protease, and intestinal acetylase, which indicated that the interference of TSN on the detoxification enzymes of P. rapae may be responsible for the toxic reaction (Zhang and Zhao, 1992a). In addition, TSN was capable of causing severe damage to midgut tissue, resulting in abscission and autolysis (Zhang and Zhao, 1991). Furthermore, the physiological metabolism of P. rapae was disturbed by TSN, and abnormal biological oxidation was induced in vivo, which demonstrated that TSN could inhibit the central nervous system of the larva (Zhang et al., 1992b).

Apart from P. rapae, TSN possessed potent growth inhibition on other species of insects—for instance, TSN possessed strong stomach toxicity against Mythimna separate (LC50 = 252.23 μg/ml), and this process was located and targeted on the microvilli of the midgut cells. Subsequently, TSN induced the destruction of midgut epithelial cells, which caused the regurgitation, paralysis, and death of M. separate (Li H. et al., 2020). Another research reported that TSN could disrupt yolk deposition in oocytes, blood ingestion and digestion, and ovary ecdysteroid production in Aedes aegypti (Ma et al., 2013). Huang et al. found that the activities of pepsase and tryptase in Brachionus plicatilis can be suppressed by TSN, which may be responsible for the feeding deterrent property (Huang et al., 2017). In order to solve the problems of biological pollution in the cultivation scale of microalgae, TSN was selected to conduct an insecticidal test. The outcomes revealed that TSN possessed obvious toxicity to Stylonychia mytilus (a type of ciliate), while it is relatively safe to Chlorella pyrenoidosa (a type of microalgae) (Xu et al., 2019). Moreover, TSN was reported to inhibit the growth of Sirophilus oryzae and Cryptolestes ferrugineus, two common store-product insects (Xie et al., 1995). In addition to the control of agricultural pests, TSN has become a clinical anti-Ascaris drug in China since the 1950s (Shi and Li, 2007).

Antifeeding and Insecticide Effects of Other Limonoids

The insect antifeedant activities of other limonoids from genus Melia plants have been extensively evaluated, and the structure–activity relationships were also discussed. By using the conventional leaf disk method, the antifeedant activity against Spodoptera eridania was tested for ohchinolide C, salannin, nimbolidin B, nimbolidin C, nimbolidin D, nimbolidin E, and nimbolidin F. The outcomes showed that these compounds, at a concentration of 500 ppm, can significantly affect feeding (Nakatani et al., 1996; Zhou et al., 1997), while trichilinin B, trichilinin C, ohchinolide B, ohchinolide C, and 3-O-acetylohchinolal exhibited a weak antifeedant activity against S. eridania at a concentration of 1,000 ppm (Nakatani, 1999). At the concentration of 400 ppm, 12-O-acetylazedarachin A, 12-O-acetylazedarachin B, trichilin H, trichilin I, trichilin J, trichilin K, and trichilin L have an inhibitory effect on the feeding amounts of leaf compared to the controls (Nakatani, 1999). It was found that 12-hydroxyamoorastatone, azedarachin A, trichilin B, and 12-hydroxyamoorastatin displayed a potential antifeedant activity with MIC values of 250, 200, 200, and 150 ppm, respectively (Zhou et al., 1996; Nakatani, 1999). At the same time, the most potent antifeedant limonoids were found to be meliacarpinin A, meliacarpinin C, and meliacarpinin D, with a MIC value of 50 ppm (Nakatani, 1999). In addition, some studies focused on discovering the effective antifeedants against Spodoptera littoralis, another kind of plant pest. As a result, nimbolinin A, nimbolinin B, nimbolinin C, nimbolinin D, trichilinin D, trichilinin E, 1-O-cinnamoyltrichilinin, 1-deacetylnimbolinin A, spirosendan, and 2-deacetylnimbolinin B exhibited a weak activity at 1,000 ppm (Nakatani et al., 2000). The MIC value of neoazedarachin A, neoazedarachin B, neoazedarachin D, 13-O-acetylazedarachin A, and 1-acetyltrichilin H against S. littoralis was 400 ppm, and the MIC value for isotoosendanin, TSN, and azedarachin B was 300, 200, and 200 ppm, respectively (Nakatani, 1999; Nakatani et al., 2000). Furthermore, 1-cinnamoyl-3-acetyl-11-hydroxymeliacarpin was found to possess an attractive insecticidal activity with a LC50 value of 0.48 ppm and a EC50 value of 0.27 ppm (Bohnenstengel et al., 1999). LC–MS guided isolation method was applied to screen promising antifeedant compounds against the fifth-instar larvae of P. rapae, and TSN, isotoosendanin, 12α-hydroxyamoorastatone, mesendanin H, meliatoosenin E, 3-O-acetylohchinolal, salannin, and ohchinal were found to inhibit the feeding ability of P. rapae. Among these compounds, mesendanin H was proven to be the most active limonoid, with an AFC50 value of 0.11 mM (Wang et al., 2020a). The antifeedant activity against Spodoptera exigua of azedarachin A, 12-O-acetylazedarachin A, 12-O-acetylazedarachin B, and 1-deoxy-3-tigloyl-11-methoxymeliacarpinin was proven, and the MIC values ranged from 200 to 400 ppm (Huang et al., 1994). For the purpose of finding novel naturally occurring insecticides from plants, Carpinella et al. evaluated the antifeedant and insecticide properties of 12α-hydroxyamoorastatone and azadirachtin against Epilachna paenulata by choice and no-choice assays. In a choice-assay study, 12α-hydroxyamoorastatone and azadirachtin inhibited feeding with ED50 values of 0.80 and 0.72 ug/cm2. These two compounds both possessed a remarkable insecticide activity, which was evidenced by low food intake, weight loss, and even significant mortality (LD50 values of 0.76 and 1.24 μg/cm2) (Carpinella et al., 2003).

Structure–Activity Relationships With Insecticidal Effect

The structure–activity relationships of limonoids have attracted extensive interest for their remarkable insecticidal activity. It was found that the highly oxidized C-seco limonoids, such as meliacarpinin-type limonoids (meliacarpinin A, meliacarpinin C, and meliacarpinin D), exhibited the most potent antifeedant activity than the less oxidized types of C-seco limonoids, such as nimbolinins (nimbolinin A and 1-deacetylnimbolinin A-B), ohchinolides (ohchinolide B-C), nimbolidins (nimbolidin B-F), and salannin. Apart from meliacarpinins, the intact trichilin-type limonoids with C-19/C-29 bridged acetals were considered as the higher active compounds, of which 12-hydroxyamoorastatin showed the most potent activity (Nakatani, 1999). In another study, the most active compound against S. eridania was azedarachin A with a 12-OH function (Zhou et al., 1996). The insecticidal activity evaluation of three meliacarpins (1,3-dicinnamoyl-11-hydroxymeliacarpin, 1-cinnamoyl-3-methacrylyl-11-hydroxymeliacarpin, and 1-cinnamoyl-3-acetyl-11-hydroxymeliacarpin) suggested that the property of the ester substituent at C-3 acted a critical role for the insecticidal effect. The results showed that 1-cinnamoyl-3-acetyl-11-hydroxymeliacarpin that bore a small and relatively hydrophilic acetyl group at C-3 possessed a high activity, while 1,3-dicinnamoyl-11-hydroxymeliacarpin with a bulky and more lipophilic cinnamoyl group exhibited the lowest activity (Bohnenstengel et al., 1999) (Figure 11).

FIGURE 11

FIGURE 11

The insecticidal structure–activity relationship of limonoids

Anti-botulinum Effect

Botulinum neurotoxin (BoNT), the strongest known biotoxin in the world, is a kind of toxin secreted by Clostridium botulinum, which includes seven distinct serotypes (identified as A to G). The nerve endings of a cholinergic neuromuscular junction are considered as its key targets. Botulinum neurotoxin can inhibit the release of acetylcholine through the enzymatic hydrolysis of SNARE protein, which plays a crucial role in neurotransmitter release. Then, the signal transmission of neuromuscular connection was further blocked to paralyze the muscle, which eventually led to the death of animals due to respiratory failure (Rossetto et al., 2014). The four-step action hypothesis, the proposed mechanism of botulinum toxin on target cells, demonstrated that botulinum toxin binds to receptors on the cell surface firstly and enters the nerve cell through receptor-mediated internalization. Subsequently, acidification of endocytic vesicles caused the translocation of light chains from the vesicles to the cytoplasm, and the light chains cleave the SNARE protein in the cytosol, thereby completing the last step of the intracellular action of the toxin (Humeau et al., 2000). TSN has been proven to block neuromuscular connection in the phrenic nerve–diaphragm specimens of rats, which was similar to that of BoNT in many aspects—for instance, the dosage–response relationship, the higher temperature coefficient, and the irreversibility of the blocking effect existed in both substances when blocking neuromuscular connections. Nevertheless, there are some differences between TSN and BoNT—for instance, TSN can cause submicroscopic changes of presynaptic motor nerve endings, which refer to the reduced number of synaptic vesicles and the widened synaptic cleft (Xiong, 1985). It was noteworthy that TSN has a facilitation phase before the final inhibition of neurotransmitter release. It means that the quantum release of acetylcholine by TSN is a biphasic regulation of facilitation followed by inhibition (Shi et al., 1982).

Interestingly, TSN, which has similar bioactive properties with BoNT, unexpectedly possesses a prominent anti-botulism effect. Early in the 1980s, TSN was proven to have an obvious therapeutic effect on BoNT-poisoned animals. In the isolated phrenic nerve and diaphragm muscle specimens of mice, both the TSN and BoNT administered simultaneously or TSN administered beforehand showed a significant antagonistic effect on BoNT (Li and Sun, 1983). The anti-botulism effect of TSN exhibited the properties of fast onset and long action time in the isolated neuromuscular specimens and rat models. In addition, TSN has a therapeutic effect on various types of botulism, such as A, B, and E, in mice and rhesus monkeys, which showed broad-spectrum anti-botulism effects (Janda, 2008). Furthermore, in a clinical study, oral administration of TSN can relieve symptoms of botulism, and the patients will recover when treated with the combination of TSN and anti-botulinum serum (Zou et al., 1985). Undoubtedly, structure–activity relationships attracted enough attention in drug research and development. Whether the unusual AB-ring of TSN is related with its anti-botulinum properties was tested. A synthetic strategy allowing access to the AB-fragment of TSN was achieved from a trans-decalin system. However, none of these synthetic structures exhibited antagonism against BoNT/A in the rat spinal cord cellular assay, which demonstrated that complete ABCD nucleus was essential for the anti-BoNT effect of TSN (Nakai et al., 2010).

Recently, the mechanism study revealed that TSN was capable of endowing neuromuscular junctions with a high tolerance to BoNT. Preincubation with TSN for 5 min can enhance the tolerance to BoNT/A in the isolated phrenic nerve and diaphragm muscle specimens of mice (Li and Sun, 1983). In another study, rat phrenic nerve–diaphragm specimens that were preincubated with TSN showed apparent antagonism to botulism, which was manifested as significantly delayed at the time of neuromuscular transmission inhibition. It was found that the anti-BoNT effect of TSN was closely related with the facilitation of neurotransmitter release induced by TSN in a time-dependent manner. In one research, rats injected with TSN (7 mg/kg, i.h.) or blank solvent were sacrificed at different time points (from 15 min to several days). The results showed that the rat phrenic nerve–diaphragm specimens exhibited high BoNT tolerance after injection with TSN, and the frequency of miniature end-plate potentials was higher than that of the control (Shih and Hsu, 1983).

In the light of the four-step action hypothesis, cleaving of SNARE protein by the light chains was considered as the final process to activate a toxic effect, therefore inhibiting the cleaving procedure emerges as a potential therapeutical strategy. Inspired by this tactic, Zhou et al. explored the anti-BoNT mechanism of TSN by Western blotting. Surprisingly, TSN treatment did not affect the expression of synaptosomal-associated protein of 25 kDa (SNAP-25), syntaxin, and synaptobrevin/vesicle-associated membrane protein in rat cerebral synaptosomes. However, it can completely antagonize the cleavage of SNAP-25 induced by BoNT/A. When BoNT acts directly on synaptosomes, TSN can still partially antagonize the cleavage of SNAP-25, but it cannot inhibit the cleavage of SNAP-25 on the synaptosome membrane by light-chain BoNT/A. Thus, the underlying mechanism of TSN against BoNT/A is to block the approach of BoNT to its enzyme substrate (Zhou et al., 2003).

As we know, cleaving of SNARE protein by light chains is a critical event in botulism, and the heavy-chain-formed channel has been confirmed to be indispensable in the translocation of the light chain into the cytosol (Blaustein et al., 1987). To verify the effect of TSN on the channel-forming activity of BoNT/A, the inside-out single-channel recording patch-clamp technique was applied to record the BoNT/A-induced currents in the presence and absence of TSN. The results showed that TSN administration could delay the channel formation and reduce the size of the channels in the PC12 cell membrane, which indicated that TSN could inhibit BoNT/A by interfering with the translocation of BoNT via inhibiting its pore-forming activity (Li and Shi, 2006).

Anti-inflammatory Effect

Limonoids from genus Melia were considered as an emerging source for discovering potential anti-inflammatory lead compounds. In a representative research, the anti-inflammatory effect of TSN was found in dextran sulfate sodium-induced colitis model. After treatment with TSN, the secretion of proinflammatory cytokines and oxidative stress were blocked, and M1 macrophage polarization and the activation of NLR family pyrin domain containing 3 inflammasome were restrained, accompanied with upregulation of HO-1/Nrf2 expression (Fan et al., 2019). In addition, acetic acid-induced vascular permeability, λ-carrageenan-induced hind paw edema tests, and acetic acid-induced writhing and hot-plate tests were applied to evaluate the anti-inflammatory effect of limonoids. As a result, two limonoids, iso-toosendanin and 1-O-tigloyl-1-O-debenzoylohchinal, isolated from the fruit of M. toosendan were proven to have anti-inflammatory and analgesic effects (Xie et al., 2008). The NF-κB pathway plays a critical role in inflammation, and one report demonstrated that 1-O-tigloyl-1-O-deacetyl-nimbolinin B (TNB) possessed the most obvious anti-inflammatory effect than the other two limonoids, including nimbolinin A and nimbolinin B, and the underlying mechanism was through suppressing NF-κB and JNK activation in microglia cells. In this study, administration with TNB can reduce the production of nitric oxide (NO) and TNF-α in lipopolysaccharide (LPS)-stimulated microglia cells (Tao et al., 2014). In another research, NF-κB luciferase assay was applied to rapidly screen potential NF-κB regulators from the fruits of M. toosendan. As a result, seven limonoids were found to inhibit NF-κB activation at the concentration of 10 μM (Zhu et al., 2014).

In the LPS-induced mouse macrophage RAW 264.7 cell inflammatory model, five limonoids, including trichilinin B, 3-deacetyl-28-oxosalannolactone, ohchinin, 23-hydroxyohchininolide, and 21-hydroxyisoohchininolide, exhibited a significant anti-inflammatory activity by inhibiting the production of NO with IC50 values from 28.7 to 87.3 μM. Meanwhile, all these five compounds displayed no or almost no toxicity to the cells (Pan et al., 2014b). Toosendane B and toosendane C, another two limonoids from the bark of M. toosendan, can also obviously reduce NO production in RAW 264.7 cells induced by LPS (Hu et al., 2018). Four NO-inhibited limonoids, including ohchinin, salannin, nimbolinin D, and mesendanin E, were isolated from M. azedarach, of which salannin was found to inhibit the expression levels of iNOS and COX-2 proteins in a concentration-dependent manner (Akihisa et al., 2017). In addition, meliazedalides B, a trichilin-class limonoid from the fruits of M. azedarach, also showed a weak anti-inflammatory effect (Qiu et al., 2019). In order to screen anti-neuroinflammatory compounds from M. azedarach, a LPS-induced microglia BV-2 cell model was established. Seven compounds, including 1-O-benzoyl-3-O-deactylnim-bolinin C, 3-deacetyl-12-O-methylvolkensin, 12-O-methyl-1-O-deacetyl-nimbolinin, trichilinin B, 1-O-cinnamoyltrichilinin, 1-acetyltrichilinin, and 12α-hydroxyamoorastatone, were isolated and confirmed as potential inhibitors of NO production, with IC50 values from 7.73 to 26.75 μM (Park et al., 2020).

Antibacterial and Antifungal Effects

Recently, several limonoids were found to possess a potential antibacterial activity. In the year 2007, 10 limonoids were isolated from the fruits of M. toosendan, among which three compounds, including 12-ethoxynimbolinins C, 1-O-cinnamoyltrichilinin, and trichilinin B, were validated to have an antibacterial activity against oral pathogen Porphyromonas gingivalis, with MIC values of 15.6, 31.3, and 31.5 μg/ml, respectively. Nevertheless, they exhibited no obvious bioactivity against Streptococcus mutans. The results indicated that these three limonoids might be specific inhibitors of P. gingivalis (Zhang et al., 2007). In 2016, this research group found that 1α,7α-ditigloyloxy-3α-acetoxyl-12α-ethoxylnimbolinin and 1α-tigloyloxy-3α-acetoxyl-7α-hydroxyl-12β-ethoxylnimbolinin, the other two new limonoids, possessed antibacterial activity against P. gingivalis, with MIC values of 15.2 and 31.25 μg/ml, respectively (Zhang et al., 2016). Unlike previously reported limonoids from fruits or bark, three limonoids were isolated from the seeds of M. azedarach, and 7-cinnamoyltoosendanin had significant inhibitory effects against Micrococcus luteus and Bacillus subtilis, with MIC values of 6.25 and 25 μg/ml, respectively (Liu et al., 2011). By using a microdilution assay, Su et al. determined the antibacterial activity of meliarachin D and meliarachin H. The results showed that meliarachin D can inhibit both Staphylococcus aureus (MIC = 50 μg/ml) and B. subtilis (MIC = 50 μg/ml); in contrast, meliarachin H can only suppress the growth of B. subtilis, with a MIC value of 25 μg/ml (Su et al., 2011).

Other Pharmacological Effects

Apart from the pharmacological effects mentioned above, limonoids also possessed some other bioactivities. In 2018, TSN was reported to exhibit anti-obesity property. By using Oil Red O staining assay, TSN could attenuate lipid accumulation in preadipocytes 3T3-L1. In addition, treatment with TSN can also decreased the mRNA and protein levels of adipocytokines (adiponectin and leptin), CCAAT/enhancer-binding proteins α, peroxisome proliferator-activated receptor γ, fatty acid synthase, and acetyl-CoA carboxylase in adipocytes. Moreover, the weight of gonadal white fat and the serum triacylglycerol content in high-fat-diet-fed mice were reduced by administration with TSN. The underlying mechanism is through activating the Wnt/β-catenin pathway (Chen et al., 2018). One study showed that, through altering polymerase acidic protein nuclear localization, TSN could inhibit early influenza A virus infection (Jin YH. et al., 2019). Similarly, hepatitis C virus infection was also inhibited by TSN. It can enhance the effect of alpha interferon (α-IFN), a classical drug in the treatment of HCV infection, and upregulate the expression of α-IFN-related protein (Watanabe et al., 2011). The pharmacological effects are summarized in Table 2.

TABLE 2

CompoundsModelsTreatmentIn vitro/vivoEffectsReference
Anti-tumor effect
Gastric cancer
ToosendaninMKN-45 cells60–100 nMIn vitroInducing apoptosisShao et al. (2020)
ToosendaninAGS cells0.5–2 μMIn vitroInhibiting cell proliferation and inducing apoptosisZhou et al. (2018)
ToosendaninHGC-27 cells0.1–0.5 μMIn vitroInhibiting cell proliferation and inducing apoptosisZhou et al. (2018)
ToosendaninSGC-7901 cells0.25–4 µMIn vitroInhibiting proliferation, invasion, migration and inducing apoptosisWang et al. (2017)
ToosendaninMGC-803 cells30–70 nMIn vitroInhibiting cell proliferationLiu et al. (2019)
ToosendaninHGC-27 cells0.6 µMIn vitroInhibiting cell proliferation and invasionLiu et al. (2019)
Trichilinin BAZ521 cellsIC50 = 58.2 µMIn vitroCytotoxicity against AZ521 cellsPan et al. (2014b)
3-Deacetyl-4′-demethyl-28-oxosalanninAZ521 cellsIC50 = 3.2 µMIn vitroInducing apoptosisPan et al. (2014b)
23-HydroxyohchininolideAZ521 cellsIC50 = 78.5 µMIn vitroCytotoxicity against AZ521 cellsPan et al. (2014b)
Meliarachin CAZ521 cellsIC50 = 1.5 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
ToosendaninAZ521 cellsIC50 = 0.009 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
12-Dehydroneoazedarachin DAZ521 cellsIC50 = 11.8 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
SalanninAZ521 cellsIC50 = 55.4 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
1-O-Decinnamoyl-1-O-benzoylohchininAZ521 cellsIC50 = 82.3 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
OhchininolideAZ521 cellsIC50 = 82.9 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
1-O-decinnamoyl-1-O-benzoylohchininolideAZ521 cellsIC50 = 34.7 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
23-HydroxyohchininolideAZ521 cellsIC50 = 78.5 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
1-O-Decinnamoyl-1-O-benzoyl-23-hydroxyohchininolideAZ521 cellsIC50 = 55.7 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
1-O-Decinnamoyl-1-O-benzoyl-28-oxoohchininAZ521 cellsIC50 = 61.7 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
Mesendanin EAZ521 cellsIC50 = 80 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
1-Benzoyl-1-detigloylohchinolalAZ521 cellsIC50 = 81.6 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
Nimbolinin DAZ521 cellsIC50 = 96.8 µMIn vitroCytotoxicity against AZ521 cellsAkihisa et al. (2013)
Trichilinin ESGC-7901 cellsIC50 = 6.9 µMIn vitroCytotoxicity against SGC-7901 cellsZhou et al. (2016)
Lung cancer
ToosendaninA549 cells, tumor xenograft model50–400 nMIn vitro and in vivoEnhancing apoptosis and inducing autophagyLi et al. (2017)
ToosendaninA549 and A549/DDP cells50 μg/mlIn vitroInducing cell growth inhibition and enhancing CDDP sensitizationZheng et al. (2018)
ToosendaninA549 and H1975 cells2–10 nMIn vitroInhibiting TGF-β1-induced EMT, adhesion, invasion, and migrationLuo et al. (2018)
ToosendaninA549 cells20–60 μMIn vitroInducing apoptosis
12-HydroxyamoorastatoneA549 cellsED50 = 0.92 μg/mlIn vitroCytotoxicity against A549 cellsAhn et al. (1994)
12-HydroxyamoorastatinA549 cellsED50 = 0.04 μg/mlIn vitroCytotoxicity against A549 cellsAhn et al. (1994)
12-AcetoxyamoorastatinA549 cellsED50 = 0.01 μg/mlIn vitroCytotoxicity against A549 cellsAhn et al. (1994)
1,12-Diacetyltrichilin BA549 cellsIC50 = 0.93 µMIn vitroCytotoxicity against A549 cellsYuan et al. (2013)
Meliarachin CA549 cellsIC50 = 63.6 µMIn vitroCytotoxicity against A549 cellsAkihisa et al. (2013)
1-O-Decinnamoyl-1-O-benzoylohchininA549 cellsIC50 = 82.3 µMIn vitroCytotoxicity against A549 cellsAkihisa et al. (2013)
1-O-Decinnamoyl-1-O-benzoyl-23-hydroxyohchininolideA549 cellsIC50 = 90.1 µMIn vitroCytotoxicity against A549 cellsAkihisa et al. (2013)
1-Benzoyl-1-detigloylohchinolalA549 cellsIC50 = 83.5 µMIn vitroCytotoxicity against A549 cellsAkihisa et al. (2013)
Colorectal cancer
 ToosendaninCRC SW480 cells0.5 µMIn vitroInducing apoptosisWang et al. (2015)
 ToosendaninHEK293T, SW620, HCT-15/5FU-R cells and BALB/c nude mice1–2 μM; 0.69 mg/kg for 22 days/i.pIn vitro and in vivoInhibiting cell proliferation and inducing apoptosisWang et al. (2020b)
 12-HydroxyamoorastatoneHCT-15 cellsED50 = 1.6 μg/mlIn vitroCytotoxicity against HCT-15 cellsAhn et al. (1994)
 12-HydroxyamoorastatinHCT-15 cellsED50 = 0.08 μg/mlIn vitroCytotoxicity against HCT-15 cellsAhn et al. (1994)
 12-AcetoxyamoorastatinHCT-15 cellsED50 = 0.04 μg/mlIn vitroCytotoxicity against HCT-15 cellsAhn et al. (1994)
 1,12-Diacetyltrichilin BSW480 cellsIC50 = 0.04 µMIn vitroCytotoxicity against SW480 cellsYuan et al. (2013)
Glioblastoma
 ToosendaninGBM U87 and C6 cell lines10 nMIn vitroInhibiting cell proliferation and inducing apoptosisCao et al. (2016)
 ToosendaninU-138MG50–150 nMIn vitroInducing apoptosisWang et al. (2020c)
Leukemia
 ToosendaninHL-60 cells12.5–100 nMIn vitroInducing apoptosisJu et al. (2012)
 ToosendaninK562 cells30, 50 nMIn vitroInhibiting cell proliferation and inducing apoptosis
 ToosendaninHL-60 cells20–80 ng/mlIn vitroInhibiting proliferation and cell cycle, inducing apoptosisJu et al. (2013)
 Trichilinin BHL-60 cellsIC50 = 22.2 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 3-Deacetyl-28-oxosalanninHL-60 cellsIC50 = 39.1 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 3-Deacetyl-4′-demethyl-28-oxosalanninHL-60 cellsIC50 = 2.8 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 OhchininHL-60 cellsIC50 = 56.3 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 23-HydroxyohchininolideHL-60 cellsIC50 = 25.1 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 21-HydroxyisoohchininolideHL-60 cellsIC50 = 22.7 µMIn vitroCytotoxicity against HL-60 cellsPan et al. (2014b)
 1,12-Diacetyltrichilin BHL-60 cellsIC50 = 0.55 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Meliarachin CHL-60 cellsIC50 = 0.65 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 ToosendaninHL-60 cellsIC50 = 0.005 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Meliarachin KHL-60 cellsIC50 = 91.4 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Meliarachin GHL-60 cellsIC50 = 82 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 12-Dehydroneoazedarachin DHL-60 cellsIC50 = 11.8 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Trichilinin DHL-60 cellsIC50 = 61.2 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-O-CinnamoyltrichilininHL-60 cellsIC50 = 5.8 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 SalanninHL-60 cellsIC50 = 67.1 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 OhchininHL-60 cellsIC50 = 56.3 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Ohchinin–acetateHL-60 cellsIC50 = 9.9 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-O-Decinnamoyl-1-O-benzoylohchininHL-60 cellsIC50 = 54.8 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 OhchininolideHL-60 cellsIC50 = 31.7 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-O-Decinnamoyl-1-O-benzoylohchininolideHL-60 cellsIC50 = 14.1 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 23-Methoxyohchininolide AHL-60 cellsIC50 = 4.9 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 23-HydroxyohchininolideHL-60 cellsIC50 = 25.1 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-O-Decinnamoyl-1-O-benzoyl-23-hydroxyohchininolideHL-60 cellsIC50 = 12.6 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 21-HydroxyisoohchininolideHL-60 cellsIC50 = 22.7 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 17-Defurano-17-oxoohchininHL-60 cellsIC50 = 50.4 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-O-Decinnamoyl-1-O-benzoyl-28-oxoohchininHL-60 cellsIC50 = 22.7 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 OhchinolalHL-60 cellsIC50 = 39.2 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Mesendanin EHL-60 cellsIC50 = 32.1 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-Benzoyl-1-detigloylohchinolalHL-60 cellsIC50 = 5.1 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 1-Cinnamoyl-1-detigloylohchinolalHL-60 cellsIC50 = 8.5 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
 Nimbolinin DHL-60 cellsIC50 = 5.4 µMIn vitroCytotoxicity against HL-60 cellsYuan et al. (2013)
Ovarian cancer
 ToosendaninCAVO-3, SKOV-3 cells500 nMIn vitroInhibiting invasion and migrationLi et al. (2018a)
 ToosendaninCAVO-3, ES-2 cells500 nMIn vitroInducing apoptosisLi et al. (2019)
 ToosendaninCAVO-3, A2870 cells500 nMIn vitroInducing apoptosisLi et al. (2018b)
 12-HydroxyamoorastatoneSKOV-3 cellsED50 = 13.7 μg/mlIn vitroCytotoxicity against SKOV-3cellsAhn et al. (1994)
 12-HydroxyamoorastatinSKOV-3 cellsED50 = 0.25 μg/mlIn vitroCytotoxicity against SKOV-3cellsAhn et al. (1994)
 12-AcetoxyamoorastatinSKOV-3 cellsED50 = 0.02 μg/mlIn vitroCytotoxicity against SKOV-3cellsAhn et al. (1994)
Hepatocellular carcinoma
 ToosendaninSMMC-7721 and Hep3B cells; BALB/c miceIC50 = 0.5 µM; IC50 = 0.9 µM, 0.69 mg/kg/day for 15 days/i.pIn vitro and in vivoInducing apoptosisHe et al. (2010)
 ToosendaninSMMC-7721, Hep3B cells0.5 μMIn vitroInhibiting cell proliferation and inducing apoptosisLiu et al. (2016)
 12-Ethoxynimbolinins GSMMC-7721 cellsIC50 = 27.6 µMIn vitroCytotoxicity against SMMC-7721 cellsZhang et al. (2018)
 1,12-Diacetyltrichilin BSMMC-7721 cellsIC50 = 0.36 µMIn vitroCytotoxicity against SMMC-7721 cellsYuan et al. (2013)
 Trichilinin EHepG2 cellsIC50 = 6.9 µMIn vitroCytotoxicity against HepG2 cellsZhou et al. (2016)
Breast cancer
 ToosendaninMCF-7/ADM cells50 nM; 0.69 mg/kg/every 2 days for 15 days/i.pIn vitro and in vivoInducing apoptosisWang et al. (2018)
 Trichilinin BSK-BR-3 cellsIC50 = 45.1 µMIn vitroCytotoxicity against SK-BR-3 cellsPan et al. (2014b)
 21-HydroxyisoohchininolideSK-BR-3 cellsIC50 = 91.5 µMIn vitroCytotoxicity against SK-BR-3 cellsPan et al. (2014b)
 Toosendansin HMCF-7 cells6.25 µMIn vitroCytotoxicity against MCF-7 cellsLi et al. (2020b)
 Meliatoxin B1MCF-7 cells6.25 µMIn vitroCytotoxicity against MCF-7 cellsLi et al. (2020b)
 1,12-Diacetyltrichilin BMCF-7 cellsIC50 = 0.06 µMIn vitroCytotoxicity against MCF-7 cellsYuan et al. (2013)
 Meliarachin CMCF-7 cellsIC50 = 90.4 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 Trichilinin DMCF-7 cellsIC50 = 41.5 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 SalanninMCF-7 cellsIC50 = 88.1 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 1-O-Decinnamoyl-1-O-benzoylohchininMCF-7 cellsIC50 = 14.9 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 1-O-Decinnamoyl-1-O-benzoylohchininolideMCF-7 cellsIC50 = 54.5 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 1-O-Decinnamoyl-1-O-benzoyl-23-hydroxyohchininolideMCF-7 cellsIC50 = 4.3 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 21-HydroxyisoohchininolideMCF-7 cellsIC50 = 91.5 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 OhchinolalMCF-7 cellsIC50 = 94.4 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 Mesendanin EMCF-7 cellsIC50 = 70.5 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 1-Benzoyl-1-detigloylohchinolalMCF-7 cellsIC50 = 85.0 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 1-Cinnamoyl-1-detigloylohchinolalMCF-7 cellsIC50 = 94.8 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
 Nimbolinin DMCF-7 cellsIC50 = 60.8 µMIn vitroCytotoxicity against MCF-7 cellsAkihisa et al. (2013)
Ewing’s sarcoma
 ToosendaninSK-ES-1 cells25, 50 µMIn vitroInducing apoptosisGao et al. (2019)
Neuroma
 ToosendaninPC12 cells0.87 µMIn vitroInducing apoptosisTang et al. (2004)
Lymphoma
 ToosendaninU937 cells0.87 µMIn vitroSuppressing the cell cycle progression and inducing apoptosisZhang et al. (2005a)
 12-Deacetyltrichilin IP388 cellsIC50 = 0.011 μg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 1-Acetyltrichilin HP388 cellsIC50 = 0.47 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 3-Deacetyltrichilin HP388 cellsIC50 = 0.045 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 1-Acetyl-3-deacetyltrichilin HP388 cellsIC50 = 0.4 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 1-Acetyl-2-deacetyltrichilin HP388 cellsIC50 = 0.66 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 Meliatoxin B1P388 cellsIC50 = 5.4 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 Trichilin HP388 cellsIC50 = 0.16 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 Trichilin DP388 cellsIC50 = 0.055 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
 1,12-Diacetyltrichilin BP388 cellsIC50 = 0.46 µg/mlIn vitroCytotoxicity against P388 cellsTakeya et al. (1996b)
Pancreatic cancer
 ToosendaninPANC-1, AsPC-1 cells; BALB/c mice200 nM; 0.2 mg/kg/day for 28 days/i.pIn vitro and in vivoInhibiting tumorous growth, inhibit migration and invasion, reversing EMTPei et al. (2017)
Oral epithelial carcinoma
 Trichilin HKB cellsIC50 = 0.11 μg/mlIn vitroCytotoxicity against P388 cellsTada et al. (1999)
 ToosendaninKB cellsIC50 = 3.82 μg/mlIn vitroCytotoxicity against P388 cellsTada et al. (1999)
 12-O-MethylvolkensinKB cellsIC50 = 8.72 μg/mlIn vitroCytotoxicity against P388 cellsTada et al. (1999)
Cervical carcinoma
 15-O-Deacetylnimbolidin BHeLa S3 cellsIC50 = 0.1 µMIn vitroCytotoxicity against Hela S3 cellsZhou et al. (2005)
 12-O-Deacetyltrichilin HHeLa S3 cellsIC50 = 0.48 µMIn vitroCytotoxicity against Hela S3 cellsZhou et al. (2005)
 15-O-Deacetyl-15-O-methylnimbolidin AHeLa S3 cellsIC50 = 37.4 µMIn vitroCytotoxicity against Hela S3 cellsZhou et al. (2005)
 15-O-Deacetyl-15-O-methylnimbolidin BHeLa S3 cellsIC50 = 28.3 µMIn vitroCytotoxicity against Hela S3 cellsZhou et al. (2005)
Melanoma
 12-HydroxyamoorastatoneSK-MEL-2 cellsIC50 = 0.38 μg/mlIn vitroCytotoxicity against SK-MEL-2 cellsAhn et al. (1994)
 12-HydroxyamoorastatinSK-MEL-2 cellsIC50 = 0.01 μg/mlIn vitroCytotoxicity against SK-MEL-2 cellsAhn et al. (1994)
 12-AcetoxyamoorastatinSK-MEL-2 cellsIC50 = 0.0007 μg/mlIn vitroCytotoxicity against SK-MEL-2 cellsAhn et al. (1994)
Central nervous system tumors
 12-HydroxyamoorastatoneXF498 cellsIC50 = 2 μg/mlIn vitroCytotoxicity against XF498 cellsAhn et al. (1994)
 12-HydroxyamoorastatinXF498 cellsIC50 = 0.02 μg/mlIn vitroCytotoxicity against XF498 cellsAhn et al. (1994)
 12-AcetoxyamoorastatinXF498 cellsIC50 = 0.007 μg/mlIn vitroCytotoxicity against XF498 cellsAhn et al. (1994)
Antifeeding and insecticide effects
 ToosendaninM. separateLC50 = 252.23 μg/mlIn vitroCausing the destruction of midgut epithelial cells, leading to the regurgitation, paralysisLi et al. (2020a)
 ToosendaninA. aegyptiLC50 = 60.8 μg/mlIn vitroDisrupting yolk deposition in oocytes, blood ingestion and digestion, and ovary ecdysteroid productionMa et al. (2013)
 ToosendaninB. plicatilis1.76–2.59 mg m−3In vitroInhibiting digestive enzymes including pepsase and tryptaseHuang et al. (2017)
 ToosendaninS. oryzae, C. ferrugineusLC50 = 675 and 875 ppm, respectivelyIn vitroReducing fecundity and expelling parasiteXie et al. (1995)
 ToosendaninS. mytilusLC50 = 6.4 μg/LIn vitroReducing the population density and fecundityXu et al. (2019)
 ToosendaninP. rapae100–1,000 μg/mlIn vitroInducing antifeeding
 ToosendaninP. rapae3 μg/pieceIn vitroReducing activity of microsomal multifunctional oxidase, protease, intestinal acetylaseZhang and Zhao (1992a)
 ToosendaninP. rapae400 ppmIn vitroDestructing midgut tissueZhang and Zhao (1991)
 ToosendaninP. rapae2 μg/pieceIn vitroInterfering physiological metabolism and inhibiting respiratory centerZhang et al. (1992b)
 Azedarachin AS. eridaniaMIC = 200 ppmIn vitroInducing antifeedingZhou et al. (1996)
 Nimbolidin FS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingZhou et al. (1997)
 Ohchinolide CS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingZhou et al. (1997)
 SalanninS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingZhou et al. (1997)
 Nimbolidin CS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingNakatani et al. (1996)
 Nimbolidin DS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingNakatani et al. (1996)
 Nimbolidin ES. eridaniaMIC = 500 ppmIn vitroInducing antifeedingNakatani et al. (1996)
 Nimbolidin BS. eridaniaMIC = 500 ppmIn vitroInducing antifeedingNakatani et al. (1996)
 ToosendaninS. littoralisMIC = 200 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Nimbolinin AS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Nimbolinin CS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Nimbolinin DS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Nimbolinin BS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Trichilinin DS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 Trichilinin ES. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 1-O-CinnamoyltrichilininS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani et al. (2000)
 1-Deoxy-3-tigloyl-11-methoxymeliacarpininS. exigua3 μg/cm2In vitroInducing antifeedingNakatani et al. (1993)
 Trichilinin BS. eridaniaMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilinin CS. eridaniaMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 12-HydroxyamoorastatinS. eridaniaMIC = 150 ppmIn vitroInducing antifeedingNakatani (1999)
 ToosendaninS. eridaniaMIC = 300 ppmIn vitroInducing antifeedingNakatani (1999)
 12-O-Acetylazedarachin AS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 13-O-Acetylazedarachin AS. littoralisMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Azedarachin BS. littoralisMIC = 200 ppmIn vitroInducing antifeedingNakatani (1999)
 12-O-Acetylazedarachin BS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin BS. eridaniaMIC = 200 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin HS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin IS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin JS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin KS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Trichilin LS. eridaniaMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 1-Acetyltrichilin HS. littoralisMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 12-HydroxyamoorastatoneS. eridaniaMIC = 250 ppmIn vitroInducing antifeedingNakatani (1999)
 IsotoosendaninS. littoralisMIC = 300 ppmIn vitroInducing antifeedingNakatani (1999)
 Neoazedarachin AS. littoralisMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Neoazedarachin BS. littoralisMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 Neoazedarachin DS. littoralisMIC = 400 ppmIn vitroInducing antifeedingNakatani (1999)
 1-Deacetylnimbolinin AS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 2-Deacetylnimbolinin BS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 Ohchinolide BS. eridaniaMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 Ohchinolide CS. eridaniaMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 3-O-AcetylohchinolalS. eridaniaMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 Meliacarpinin AS. eridaniaMIC = 50 ppmIn vitroInducing antifeedingNakatani (1999)
 Meliacarpinin CS. eridaniaMIC = 50 ppmIn vitroInducing antifeedingNakatani (1999)
 Meliacarpinin DS. eridaniaMIC = 50 ppmIn vitroInducing antifeedingNakatani (1999)
 SpirosendanS. littoralisMIC = 1,000 ppmIn vitroInducing antifeedingNakatani (1999)
 1-Cinnamoyl-3-acetyl-11-hydroxymeliacarpinS. littoralisEC50 = 0.27 ppmIn vitroInducing antifeedingBohnenstengel et al. (1999)
 ToosendaninP. rapaeAFC50 = 0.21 mMIn vitroInducing antifeedingWang et al. (2020a)
 IsotoosendaninP. rapaeAFC50 = 0.46 mMIn vitroInducing antifeedingWang et al. (2020a)
 12α-HydroxyamoorastatoneP. rapaeAFC50 = 0.64 mMIn vitroInducing antifeedingWang et al. (2020a)
 Mesendanin HP. rapaeAFC50 = 0.11 mMIn vitroInducing antifeedingWang et al. (2020a)
 Meliatoosenin EP. rapaeAFC50 = 1.03 mMIn vitroInducing antifeedingWang et al. (2020a)
 3-O-AcetylohchinolalP. rapaeAFC50 = 0.89 mMIn vitroInducing antifeedingWang et al. (2020a)
 SalanninP. rapaeAFC50 = 1.35 mMIn vitroInducing antifeedingWang et al. (2020a)
 OhchinalP. rapaeAFC50 = 1.79 mMIn vitroInducing antifeedingWang et al. (2020a)
 12α-HydroxyamoorastatoneE. paenulataLD50 = 0.76 μg/cm2In vitroInducing antifeeding and deathCarpinella et al. (2003)
 AzadirachtinE. paenulataLD50 = 1.24 μg/cm2In vitroInducing antifeeding and deathCarpinella et al. (2003)
 ToosendaninE. paenulataED50 = 3.69 μg/cm2In vitroInducing antifeedingCarpinella et al. (2003)
 Azedarachin AS. exiguaMIC = 200 ppmIn vitroInducing antifeedingHuang et al. (1994)
 12-O-Acetylazedarachin AS. exiguaMIC = 400 ppmIn vitroInducing antifeedingHuang et al. (1994)
Anti-botulinum effect
 Toosendaninmice9 mg/kg i.pIn vivoCausing submicroscopic changes of presynaptic motor nerve endingsXiong (1985)
 ToosendaninKM mice8 mg/kg i.pIn vivoMaking the synaptosomes completely resistant to botulinum neurotoxin A-mediated cleavage of SNAP-25Zhou et al. (2003)
 ToosendaninPC12 cells35 μMIn vitroDelaying channel formation and reducing the sizes of the channelsLi and Shi (2006)
 Toosendaninmice10–5 g/mlIn vivoProlonging the paralysis time of botulism specimensLi and Sun (1983)
 Toosendaninrats8 mg/kg i.pIn vivoProlonging the paralysis time of botulism specimensLi and Sun (1983)
 Toosendaninrats7 mg/kg i.hIn vivoIncreasing the frequency of miniature end-plate potentialsShih and Hsu (1983)
Anti-inflammatory effects
 1-O-Tigloyl-1-O-deacetyl-nimbolinin BBV-2 cellsIC50 = 7.892 μMIn vitroInhibiting LPS-stimulated inflammatory via blocking the activation of NF-κB and JNK signaling pathwaysTao et al. (2014)
 Trichilinin BRAW 264.7 cellsIC50 = 29.2 μMIn vitroInhibiting LPS-stimulated inflammatoryPan et al. (2014b)
 3-Deacetyl-28-oxosalannolactoneRAW 264.7 cellsIC50 = 86 μMIn vitroInhibiting LPS-stimulated inflammatoryPan et al. (2014b)
 OhchininRAW 264.7 cellsIC50 = 28.7 μMIn vitroInhibiting LPS-stimulated inflammatoryPan et al. (2014b)
 23-HydroxyohchininolideRAW 264.7 cellsIC50 = 58.6 μMIn vitroInhibiting LPS-stimulated inflammatoryPan et al. (2014b)
 21-HydroxyisoohchininolideRAW 264.7 cellsIC50 = 87.3 μMIn vitroInhibiting LPS-stimulated inflammatoryPan et al. (2014b)
 Toosendane BRAW 264.7 cellsIC50 = 21.3 μMIn vitroInhibiting LPS-stimulated inflammatoryHu et al. (2018)
 Toosendane CRAW 264.7 cellsIC50 = 20.7 μMIn vitroInhibiting LPS-stimulated inflammatoryHu et al. (2018)
 OhchininRAW 264.7 cellsIC50 = 28.7 μMIn vitroInhibiting LPS-stimulated inflammatoryAkihisa et al. (2017)
 SalanninRAW 264.7 cellsIC50 = 27.9 μMIn vitroInhibiting LPS-stimulated inflammatory via reducing the expression of iNOS and COX-2Akihisa et al. (2017)
 Nimbolinin DRAW 264.7 cellsIC50 = 24.4 μMIn vitroInhibiting LPS-stimulated inflammatoryAkihisa et al. (2017)
 Mesendanin ERAW 264.7 cellsIC50 = 23.8 μMIn vitroInhibiting LPS-stimulated inflammatoryAkihisa et al. (2017)
 12-Ethoxynimbolinin AHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 Nimbolinin CHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 1-O-Tigloyl-1-O-debenzoylohchinalHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 1-AcetyltrichilininHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 Trichilinin BHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 1-O-CinnamoyltrichilininHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 Trichilinin DHepG2 cells10 μMIn vitroSuppressing NF-κB activationZhu et al. (2014)
 IsotoosendaninMice100 mg/kgIn vivoInhibiting acetic acid-induced vascular permeability and λ-carrageenan induced hind paw edemaXie et al. (2008)
 1-O-Tigloyl-1-O-debenzoylohchinalMice100 mg/kgIn vivoInhibiting acetic acid-induced vascular permeability and λ-carrageenan induced hind paw edemaXie et al. (2008)
 Meliazedalides BRAW 264.737.41 μMIn vitroInhibiting LPS-stimulated inflammatoryQiu et al. (2019)
 1-O-benzoyl-3-O-deactylnim-bolinin CBV-2 cells21.95 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 3-Deacetyl-12-O-methylvolkensinBV-2 cells21.37 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 12-O-Methyl-1-O-deacetyl-nimbolininBV-2 cells23.16 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 Trichilinin BBV-2 cells15.28 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 1-O-CinnamoyltrichilininBV-2 cells7.73 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 1-AcetyltrichilininBV-2 cells20.61 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 12α-HydroxyamoorastatoneBV-2 cells26.75 μMIn vitroInhibiting LPS-stimulated inflammatoryPark et al. (2020)
 ToosendaninMice0.5, 1.0 mg/kg i.p. for 7 daysIn vivoAlleviating DSS-induced colitis via inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signalingFan et al. (2019)
Antibacterial and antifungal effects
 1α,7α-Ditigloyloxy-3α-acetoxyl-12α-ethoxylnimbolininP. gingivalisMIC = 15.2 μg/mlIn vitroInhibitory effects against P. gingivalisZhang et al. (2016)
 1α-Tigloyloxy-3α-acetoxyl-7α-hydroxyl-12β-ethoxylnimbolininP. gingivalisMIC = 31.25 μg/mlIn vitroInhibitory effects against P. gingivalisZhang et al. (2016)
 12-Ethoxynimbolinins CP. gingivalisMIC = 15.6 μg/mlIn vitroInhibitory effects against P. gingivalisZhang et al. (2007)
 1-O-CinnamoyltrichilininP. gingivalisMIC = 31.3 μg/mlIn vitroInhibitory effects against P. gingivalisZhang et al. (2007)
 Trichilinin BP. gingivalisMIC = 31.5 μg/mlIn vitroInhibitory effects against P. gingivalisZhang et al. (2007)
 7-CinnamoyltoosendaninM. luteusMIC = 6.25 μg/mlIn vitroInhibitory effects against M. luteusLiu et al. (2011)
 7-CinnamoyltoosendaninB. subtilisMIC = 25 μg/mlIn vitroInhibitory effects against B. subtilisLiu et al. (2011)
 Meliarachin DS. aureusMIC = 50 μg/mlIn vitroInhibitory effects against S. aureusSu et al. (2011)
 Meliarachin DB. subtilisMIC = 50 μg/mlIn vitroInhibitory effects against B. subtilisSu et al. (2011)
 Meliarachin HB. subtilisMIC = 25 μg/mlIn vitroInhibitory effects against B. subtilisSu et al. (2011)

Pharmacological effects of limonoids.

Pharmacokinetics of Limonoids

There are few investigations on the pharmacokinetics of limonoids, and only several studies focus on the pharmacokinetics of TSN for elucidating the bioactivity and toxicity mechanism. In 2012, the first UPLC–MS/MS method was established for the pharmacokinetic determination of TSN in the rat plasma sample. The results showed that TSN possessed a fast absorption rate with a Tmax (h) value of 0.63 h after oral administration. In terms of Vd level, oral administration (444,380.3 ± 204,747.7 ml/kg) had a wider distribution than intravenous administration (32,062.4 ± 18,562.8 ml/kg). Moreover, there was a significant variation of clearance between the two types of administration, and the results showed that TSN had a quick elimination rate for oral administration. However, the Cmax values of TSN were found to be at a low level despite a high oral administration dose of 60 mg/kg body weight in rat. Furthermore, this study also found a low bioavailability of TSN (9.9%), which suggested that the bioactivity and toxicity of TSN may be related with its metabolites (Wang et al., 2013). In order to analyze metabolites, the human liver microsomes were incubated with TSN, and these metabolites of TSN were identified by ultra-high performance liquid chromatography–quadrupole-time of flight mass spectrometry. Six metabolites (M1–M6) were tentatively deduced by MS spectra information. Among them, M1, M2, and M3 were produced by oxidation of TSN, and M6 was produced by dehydrogenation of TSN, while M4 and M5 can be obtained by oxidation and dehydrogenation. It is worth noting that the stability of metabolites varied in terms of time, and M1–M5 possessed strong stability, which can last for 120 min. By contrast, M6 reached a maximum value at 20 min and then decreased gradually. These evidence provide powerful founding for unraveling the metabolic fate of TSN (Wu et al., 2013).

The reactive metabolites, which were formed by the bioactivation of drugs, can partially induce liver injury by causing protein dysfunction and DNA damage (Holt and Ju, 2006). According to reports, several compounds possessed apparent toxicity, which can be ascribed to the bioactivated furan ring (Druckova et al., 2007). Therefore, the TSN that contains a structural alert of the furan ring needs to be explored comprehensively for its metabolites and the bioactivation mechanism. One research showed that esterolysis and conjugation with amino acids were proved as the principal metabolic pathways of TSN. Further experiments found that CYP3A4 could bioactivate the furan ring and produce a cis-butene-1,4-dial intermediate, and the products possibly interacted with peptides or proteins, which might account for the hepatotoxicity caused by TSN. In addition, N-conjugation of the furan ring from diverse amino acids and glutathione (GSH), rather than the widely accepted S-conjugation, acted a key role in the elimination of reactive metabolites of TSN (Yu et al., 2014). Some studies also discussed the potential detoxification mechanism from the aspect of pharmacokinetics. After the combination use of trans-anethole, the Cmax (294.8 ± 92.01 ng/L), AUC(0–t) (347.2 ± 128.7 ng/Lh), AUC(0–∞) (475.6 ± 210.8 ng/Lh), MRT(0–t) (2.667 ± 0.989 h), and MRT(0–∞) (5.386 ± 2.886 h) of TSN were decreased significantly, while the values of Vz/F (8.110 ± 5.502 L/kg) were notably increased. These outcomes indicated that co-administration of trans-anethole can decrease the absorption and bioavailability of TSN and shorten the elimination process of TSN, which reduced the risk of toxicity accumulation (Yu et al., 2020).

Toxicity of Limonoids

Although limonoids, especially TSN, possess multiple biological activities, such as anti-tumor effect, insecticidal effect, anti-botulinum effect, anti-inflammation effect, etc., a few toxic activities have also been discovered and gradually received attention (Table 3). M. toosendan and M. azedarach were recorded with mild toxicity in Chinese Pharmacopoeia. A large body of evidence found TSN as the main bioactive compound of these two herbs and is also responsible for their toxicity. In vivo and in vitro experiments have proven that hepatotoxicity, pregnancy-toxicity, and embryotoxicity were the primary toxic effects of TSN. In order to verify whether serum miRNAs can be used as potential indicators of hepatotoxicity induced by TSN, miRNA chip analysis was applied to detect the target miRNAs in serum. The experiment results showed that administration with TSN (10 mg/kg) could induce severe liver injury, which manifested as increased alanine aminotransferase/aspartate aminotransferase (ALT/AST) activity and typical pathological changes. Compared to the variation of ALT/AST activity, 22 potential miRNAs can better reflect the characteristics of liver toxicity induced by TSN. According to this research, the increased expression of miRNA-122-3p and mcmv-miRNA-m01-4-3p both existed in the TSN group and other hepatotoxicant groups, including acetaminophen, monocrotaline, and diosbuibin B. Interestingly, increased miRNA-367-3p was only found in the TSN group, which indicated that it could be used as a characteristic biomarker for discovering and discriminating TSN-induced liver injury (Yang et al., 2019).

TABLE 3

CompoundsToxic typeModelLD50/toxic dose rangeToxic reactionsReference
ToosendaninPregnancy toxicityMice0.2–0.8 mg/kg (i.p. for 7 days)Increasing the level of IFN-γ, TNF-α, CD4+, and CD8+ T lymphocytesZhang et al. (2010a)
ToosendaninHepatotoxicityMice10 mg/kg (i.p. for 6, 12, 24 h)Increasing the level of serum ALT and AST and decreasing the expression of mir-367-3pYang et al. (2019)
ToosendaninHepatotoxicityMice80 mg/kg (i.p. for 9 days)Decreasing the body weight, increasing the level of serum ALT and AST, and enhancing the expression of Fmo3Lu et al. (2016)
ToosendaninHepatotoxicityMice3.75–15 mg/kg (i.p. for 24 h)Decreasing the body weight, increasing the level of serum ALT and AST, and inducing energy metabolism disorder and hepatic steatosisYan et al. (2019)
ToosendaninHepatotoxicityPrimary hepatocyte cellsIC50 = 30.65 μMPromoting Na+ influx and K+ efflux, decreasing the size of the cell membrane, and increasing the cell membrane permeabilityYan et al. (2019)
ToosendaninHepatotoxicityMice10 mg/kg (i.p. for 6, 12, 24 h)Increasing the level of serum ALT, AST, ALP, TBIL, ROS, and MDA and decreasing GSH content and Nrf2 expressionJin et al. (2019b)
ToosendaninHepatotoxicityL-02 cells2–10 μMReducing GCL activity, GSH content, and expression of GCLC/GCLM and Nrf2; increasing ROS and Keap1 expressionJin et al. (2019b)
ToosendaninHepatotoxicityPrimary hepatocyte cellsIC50 = 14.94 μMInducing mitochondrial dysfunction and caspase activationZhang et al. (2008)
ToosendaninEmbryotoxicityMice0.46 mg/kg (i.p. for 3 days)Inducing abortionZhang et al. (2005b)

Toxicities and side effects of limonoids.

Aside from investigating the role of miRNA expression alone, Lu et al. integrated the expression of microRNA with mRNA to explore the intricate and dynamic behavior of liver injury induced by TSN. An apparent liver injury was found 9 days after administration with TSN (80 mg/kg). Unexpectedly, the damage will be restored after 21 days of administration with TSN (80 mg/kg), which may account for liver regeneration. In addition, there existed dose- and time-specific alterations in global miRNA and mRNA expressions after being exposed to TSN. It can be inferred that the liver injury started with glutathione depletion, accompanied by mitochondrial dysfunction and lipid dysmetabolism, finally leading to hepatocyte necrosis in the liver from functional analyses of the miRNA–mRNA intersection dataset (Lu et al., 2016).

The application of multi-omics strategy, including proteomics and metabolomics, was considered as an advanced approach to explain the toxicity mechanism of TSN. Yan et al. found that triosephosphate isomerase 1 (TPI1) and α-enolase (ENOA), two glycolytic enzymes responsible for hepatotoxicity, were covalently modified by reactive metabolites of TSN. In vitro and in vivo experiments indicated that modifications would reduce the activity of TPI1 while inducing the activity of ENOA. Alterations of metabolites were also monitored and analyzed by metabolomics, and the outcomes showed a downward trend in tricarboxylic acid cycle, fatty acid β-oxidation, and amino acid metabolism, which revealed that the hepatocyte energy metabolism disorder could be induced by TSN (Yan et al., 2019). In another study, the role of Nrf2/GCL/GSH antioxidant signaling pathway in preventing hepatotoxicity from TSN was elucidated. It was found that TSN can decrease GSH content and Nrf2 expression, increase the expression of the Nrf2 inhibitor protein Kelch-like ECH-associated protein-1, and finally block the antioxidant signaling pathway to induce liver oxidative injury. Quercetin, a natural flavonoid with marked antioxidant ability, was validated to alleviate liver injury caused by TSN, which provided a new insight into compatibility detoxification of drugs (Jin Y. et al., 2019). In addition, fructus foeniculi, a typical detoxification drug for toosendan fructus, was reported to eliminate the toxicity of TSN by decreasing the absorption and bioavailability and accelerating the elimination process (Yu et al., 2020).

Since apoptosis plays an important role in inducing cell death, and TSN can exert its anti-tumor effect through the apoptotic pathway, whether apoptosis also acts as a critical regulator in liver damage caused by TSN needs further exploration. One representative study showed that TSN could inhibit primary rat hepatocyte growth with an IC50 value of 14.94 μM for 24 h. The underlying mechanism can be illustrated as TSN caused a decrease of mitochondrial membrane potential and intracellular ATP level and released cytochrome c to the cytoplasm, ultimately activating caspase-8, -9, and -3 to induce cell death. In the meantime, the activation of ROS and MAP kinases was also involved in this process (Zhang et al., 2008).

In recent years, with the increasing adverse effects of plant and vegetable pesticide residues on pregnant female individuals, the reproductive toxicity of TSN was also explored. The first study of reproductive toxicity caused by TSN was conducted by the team of Zhang, and they found that an intraperitoneal injection of TSN (0.46 mg/kg) could cause specific embryotoxicity to pregnant mice (Zhang X. F. et al., 2005). Later, in another study, the authors found that TSN-induced abortion was related with the imbalance of Th1/Th2 type cytokines, which manifested as increased levels of TNF-α and IFN-γ and CD4+/CD8+ ratio. These results partially proved that the immune imbalance is an important event in the reproductive toxicity induced by TSN (Zhang JL. et al., 2010).

The potential toxicity of limonoids has been noticed and emphasized in clinical application. Furthermore, the two herbs were commonly processed prior to clinical use, which can considerably reduce the toxicity. In addition, the compatibility of multiple herbs is another feasible method for toxicity reduction. In fact, countless innovative drugs, including atropine, scopolamine, and anisodamine, from Chinese medicinal herbs are toxic, but they are widely used for clinical purposes after an in-depth study. Therefore, the toxic limonoids (mainly focused on hepatotoxicity) could be candidate drugs via structural modification or targeted drug delivery.

Conclusion

Taken together, the limonoids isolated from genus Melia possess certain similar skeleton structures and can be classified into diverse types, including trichilin class, vilasinin class, havanensin class, azadirone class, nimbolinin class, nimbolidin class, salannin class, ohchinolal class, meliacarpinin class, meliacarpin class, and others. Although enormous attempts have been devoted to synthesize, semi-synthesize, and biosynthesize the momentous TSN and other limonoids, no ideal tactic was established for the complicated synthesis process yet. Limonoids, which possess promising bioactivities, such as anti-tumor activity, antifeeding activity, anti-botulism effect, anti-inflammatory effect, and antibacterial effect, have obtained global acceptance in agricultural applications and contemporary medicine. In the meantime, the structure-related activity, toxic effects, and pharmacokinetics have also been summarized in this review. Notwithstanding that great breakthroughs have been made in the comprehensive exploration and application of limonoids, some in-depth works are still extremely urgent to be conducted in the future.

Firstly, as a marker of bioactivity and toxicity of M. toosendan and M. azedarach, TSN has a rigorous criterion for its content limit. Owing to the presence of a hemiacetal structure in the molecular structure, tautomerism will occur, which implies that there are two chromatographic peaks when detecting the content of TSN. In addition, the tautomerism also existed in 1-deacetylnimbolinin B, nimbolinin B, nimbolinin A, and 1-O-tigloyl-1-O-deacetyl-nimbolinin B (Shen et al., 2014). Even though the content of these compounds can be measured by calculating the sum of the areas of the two peaks, it is important to find another strategy to address this dilemma. Confused by this phenomenon, some researchers tried to utilize acetylation reactions to make 28-OH become a single compound. Nevertheless, this approach was difficult to achieve completely due to the small amount of acetic anhydride and pyridine and was not suitable for extracts of toosendan fructus and meliae cortex (Zhong et al., 1975). Since a tautomer may exert different roles in the treatment of diseases, even the opposite effect, it is therefore crucial to figure out whether there is any difference in bioactivity between the two tautomers.

Secondly, although diverse pharmacological activities of limonoids have been confirmed, their definite molecular targets are still unclear. Given the promising anti-tumor bioactivity against various types of cancers, more studies should be devoted to molecular and cellular mechanism research through the combination of metabolomics and proteomics. To date, there is a large body of research focusing on the pharmacological activities of limonoids by animal or in vitro cell models. However, few clinical trials have been exerted, which restricted its application. We have searched clinical trials of limonoids in “ClinicalTrials.gov” and “trialsearch.who.int”, but only one study was conducted to investigate the anti-hypercholesterolemic effect of a limonoid-rich beverage, and no results were posted. We acknowledge that it is a long journey from the discovery of natural bioactive compounds to the development of new drugs. Due to the reported side effect, the potential clinical trials of limonoids were limited. Nevertheless, cautious clinical trials are necessary after reasonable structural modification and toxicity evaluation.

Thirdly, an increasing number of studies reported the toxic effects of limonoids, and TSN has received the most attention. It was reported that hepatotoxicity was considered as the predominant toxicity, which is of great concern worldwide. Nevertheless, few studies focused on the toxicity of other limonoids that have a skeleton structure similar to that of TSN. Previous reports showed that the content of 1-deacetylnimbolinin B was higher than TSN in fructus toosendan, and the contents of nimbolinin B, nimbolinin A, and 1-O-tigloyl-1-O-deacetyl-nimbolinin B exhibited no noticeable difference with TSN (Shen et al., 2014). Thus, it is indispensable to carry out extensive toxicity screening of other limonoids for the comprehensive quality control of fructus toosendan and meliae cortex. Moreover, the lack of a clear toxicity mechanism seriously restricts its clinical application. Hence, the toxic molecular target and the metabolism changes in vivo, accompanied with potential detoxification and/or a toxicity enhancement metabolism pathway, need to be further explored. Interestingly, processing can reduce the toxicity of fructus toosendan, which suggests that heating, acidification, and other physical processes may transform toxic limonoids into less toxic compounds. Although the synthesis of toosendanin is challenging yet, a breakthrough has been made in the synthesis of azadirachtin (one limonoid of genus Azadirachta), which points out the direction of future study. The successful total synthesis was achieved by the strategy called “relay route” or “relay synthesis”, which attempted to degrade azadirachtin to a specific potential synthetic intermediate and then transform this back into the natural product. Therefore, a similar strategy is expected to be applied in the synthesis of toosendanin.

Statements

Author contributions

WF contributed to writing—original draft. LF contributed to resources. ZW contributed to conceptualization and supervision. LY contributed to conceptualization, writing—review and editing, and supervision.

Funding

This work is financially supported by the Program of Shanghai Municipal Commission of Health and Family Planning (ZY (2021-2023)-0215) and Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine. (ZYYCXTD-D-202004).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Glossary

  • Cyt C

    Cytochrome c

  • AIF

    Apoptosis-inducing factor

  • Caspase

    Cysteinyl aspartate-specific proteinase

  • Apaf-1

    Apoptotic protease-activating factor-1

  • Bcl-2

    B-cell lymphoma-2

  • PARP

    Poly-ADP-ribose polymerase

  • TNFR

    Tumor necrosis factor receptor

  • DR

    Death receptor

  • FADD

    Fas-associated death domain protein

  • DD

    Death domain

  • DED

    Death effector domain

  • DISC

    Death-inducing signaling complex

  • TRAIL

    Tumor necrosis factor (TNF)-related apoptosis-inducing ligand

  • DR5

    Death receptor 5

  • CHOP

    CCAAT/enhancer-binding protein homologous protein

  • ROS

    Reactive oxygen species

  • JNK

    c-Jun N-terminal kinase

  • miRNAs

    MicroRNAs

  • EMT

    Epithelial–mesenchymal transition

  • ECM

    Extracellular matrix

  • TGF-β1

    Transforming growth factor-β1

  • NSCLC

    Non-small cell lung cancer

  • ADM

    Adriamycin

  • SAR

    Structure–activity relationships

  • DDS

    Dextran sulfate sodium

  • NLRP3

    NLR family pyrin domain containing 3

  • NO

    Nitric oxide

  • TNF

    Tumor necrosis factor

  • iNOS

    Inducible nitric oxide synthase

  • COX-2

    Cyclooxygenase

  • IL

    Interleukin

  • LPS

    Lipopolysaccharide

  • C/EBP-α

    CCAAT/enhancer-binding proteins α

  • PPAR-γ

    Peroxisome proliferator-activated receptor γ

  • HFD

    High-fat diet

  • α-IFN

    Alpha interferon

  • GSH

    Glutathione

  • ALT

    Alanine aminotransferase

  • AST

    Aspartate aminotransferase

  • TPI1

    Triosephosphate isomerase 1

  • ENOA

    α-Enolase

  • Keap1

    Kelch-like ECH-associated protein-1

References

  • 1

    AhnJ.-W.ChoiS.-U.LeeC.-O. (1994). Cytotoxic Limonoids from Melia Azedarach Var. Japonica. Phytochemistry36, 14931496. 10.1016/s0031-9422(00)89749-6

  • 2

    AkihisaT.NishimotoY.OgiharaE.MatsumotoM.ZhangJ.AbeM. (2017). Nitric Oxide Production-Inhibitory Activity of Limonoids from Azadirachta indica and Melia Azedarach. Chem. Biodivers.14. 10.1002/cbdv.201600468

  • 3

    AkihisaT.PanX.NakamuraY.KikuchiT.TakahashiN.MatsumotoM.et al (2013). Limonoids from the Fruits of Melia Azedarach and Their Cytotoxic Activities. Phytochemistry89, 5970. 10.1016/j.phytochem.2013.01.015

  • 4

    AshkenaziA.PaiR. C.FongS.LeungS.LawrenceD. A.MarstersS. A.et al (1999). Safety and Antitumor Activity of Recombinant Soluble Apo2 Ligand. J. Clin. Invest.104, 155162. 10.1172/jci6926

  • 5

    BarqueroA. A.MicheliniF. M.AlchéL. E. (2006). 1-Cinnamoyl-3,11-dihydroxymeliacarpin Is a Natural Bioactive Compound with Antiviral and Nuclear Factor-kappaB Modulating Properties. Biochem. Biophys. Res. Commun.344, 955962. 10.1016/j.bbrc.2006.03.226

  • 6

    BlausteinR. O.GermannW. J.FinkelsteinA.DasGuptaB. R. (1987). The N-Terminal Half of the Heavy Chain of Botulinum Type A Neurotoxin Forms Channels in Planar Phospholipid Bilayers. FEBS Lett.226, 115120. 10.1016/0014-5793(87)80562-8

  • 7

    BohnenstengelF. I.WrayV.WitteL.SrivastavaR. P.ProkschP. (1999). Insecticidal Meliacarpins (C-Seco Limonoids) from Melia Azedarach. Phytochemistry50, 977982. 10.1016/s0031-9422(98)00644-x

  • 8

    BurrisH. A. (2013). Overcoming Acquired Resistance to Anticancer Therapy: Focus on the PI3K/AKT/mTOR Pathway. Cancer Chemother. Pharmacol.71, 829842. 10.1007/s00280-012-2043-3

  • 9

    CampbellK. J.TaitS. W. G. (2018). Targeting BCL-2 Regulated Apoptosis in Cancer. Open Biol.8, 11. 10.1098/rsob.180002

  • 10

    CaoL.QuD.WangH.ZhangS.JiaC.ShiZ.et al (2016). Toosendanin Exerts an Anti-cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and P53-Mediated Apoptosis. Int. J. Mol. Sci.17. 10.3390/ijms17111928

  • 11

    CarpinellaM. C.DefagoM. T.ValladaresG.PalaciosS. M. (2003). Antifeedant and Insecticide Properties of a Limonoid from Melia Azedarach (Meliaceae) with Potential Use for Pest Management. J. Agric. Food Chem.51, 369374. 10.1021/jf025811w

  • 12

    ChenL.ZhangJ. X.WangB.MuS. Z.HaoX. J. (2014). Triterpenoids with Anti-tobacco Mosaic Virus Activities from Melia Toosendan. Fitoterapia97, 204210. 10.1016/j.fitote.2014.06.010

  • 13

    ChenT. X.ChengX. Y.WangY.YinW. (2018). Toosendanin Inhibits Adipogenesis by Activating Wnt/β-Catenin Signaling. Sci. Rep.8, 4626. 10.1038/s41598-018-22873-x

  • 14

    Chinese Pharmacopoeia Commission (2020). Pharmacopoeia of the People’s republic of China[M]. Beijing, China: China Medical Science and Technology Press, p4444.

  • 15

    D'AmbrosioM.GuerrieroA. (2002). Degraded Limonoids from Melia Azedarach and Biogenetic Implications. Phytochemistry60, 419424. 10.1016/s0031-9422(02)00107-3

  • 16

    DongS. H.ZhangC. R.HeX. F.LiuH. B.WuY.YueJ. M. (2010). Mesendanins A-J, Limonoids from the Leaves and Twigs of Melia Toosendan. J. Nat. Prod.73, 13441349. 10.1021/np100150n

  • 17

    DruckovaA.MernaughR. L.HamA. J.MarnettL. J. (2007). Identification of the Protein Targets of the Reactive Metabolite of Teucrin A In Vivo in the Rat. Chem. Res. Toxicol.20, 13931408. 10.1021/tx7001405

  • 18

    EstaquierJ.ValletteF.VayssiereJ.-L.MignotteB. (2012). “The Mitochondrial Pathways of Apoptosis,” in Advances in Mitochondrial Medicine. Editors ScatenaR.BottoniP.GiardinaB. (Berlin: Springer-Verlag Berlin), 157183. 10.1007/978-94-007-2869-1_7

  • 19

    FanH.ChenW.ZhuJ.ZhangJ.PengS. (2019). Toosendanin Alleviates Dextran Sulfate Sodium-Induced Colitis by Inhibiting M1 Macrophage Polarization and Regulating NLRP3 Inflammasome and Nrf2/HO-1 Signaling. Int. Immunopharmacol.76, 105909. 10.1016/j.intimp.2019.105909

  • 20

    FiandaloM. V.KyprianouN. (2012). Caspase Control: Protagonists of Cancer Cell Apoptosis. Exp. Oncol.34, 165175.

  • 21

    FriesenC.FuldaS.DebatinK. M. (1997). Deficient Activation of the CD95 (APO-1/Fas) System in Drug-Resistant Cells. Leukemia11, 18331841. 10.1038/sj.leu.2400827

  • 22

    GaoT.XieA.LiuX.ZhanH.ZengJ.DaiM.et al (2019). Toosendanin Induces the Apoptosis of Human Ewing's Sarcoma Cells via the Mitochondrial Apoptotic Pathway. Mol. Med. Rep.20, 135140. 10.3892/mmr.2019.10224

  • 23

    GoerlichB. (1960). Chemical Assay of the Glycosides with Cardiac Effect in Scilla Maritima l., Var. alba. Arzneimittelforschung10, 770774.

  • 24

    HeY.WangJ.LiuX.ZhangL.YiG.LiC.et al (2010). Toosendanin Inhibits Hepatocellular Carcinoma Cells by Inducing Mitochondria-dependent Apoptosis. Planta Med.76, 14471453. 10.1055/s-0029-1240902

  • 25

    HoltM. P.JuC. (2006). Mechanisms of Drug-Induced Liver Injury. AAPS J.8, E48E54. 10.1208/aapsj080106

  • 26

    HuJ.-F.FanH.WangL.-J.WuS.-B.ZhaoY. (2011). Limonoids from the Fruits of Melia Toosendan. Phytochemistry Lett.4, 292297. 10.1016/j.phytol.2011.05.003

  • 27

    HuQ.HuangF.ShiY. (1997). Inhibition of Toosendanin on the Delayed Rectifier Potassium Current in Neuroblastoma X Glioma NG108-15 Cells. Brain Res.751, 4753. 10.1016/s0006-8993(96)01389-3

  • 28

    HuY.HengL.XuR.LiJ.WeiS.XuD.et al (2018). Meliacarpinin-Type Limonoids from the Bark of Melia Toosendan. Molecules23. 10.3390/molecules23102590

  • 29

    HuangR. C.OkamuraH.IwagawaT.NakataniM. (1994). The Structures of Azedarachins, Limonoid Antifeedants from ChineseMelia azedarachLinn. Bcsj67, 24682472. 10.1246/bcsj.67.2468

  • 30

    HuangR. C.TaderaK.YagiF.MinamiY.OkamuraH.IwagawaT.et al (1996). Limonoids from Melia Azedarach. Phytochemistry43, 581583. 10.1016/0031-9422(96)00353-6

  • 31

    HuangY.LiuJ.PangT.LiL. (2017). Growth Inhibitory and Antifeedant Effects of Sublethal Concentrations of Toosendanin on the Rotifer Brachionus plicatilis. Biomass and Bioenergy99, 3137. 10.1016/j.biombioe.2017.02.013

  • 32

    HumeauY.DoussauF.GrantN. J.PoulainB. (2000). How Botulinum and Tetanus Neurotoxins Block Neurotransmitter Release. Biochimie82, 427446. 10.1016/s0300-9084(00)00216-9

  • 33

    JafriM. A.Al-QahtaniM. H.ShayJ. W. (2017). Role of miRNAs in Human Cancer Metastasis: Implications for Therapeutic Intervention. Semin. Cancer Biol.44, 117131. 10.1016/j.semcancer.2017.02.004

  • 34

    JandaK. D. (2008). Small Molecule Therapeutic Approaches for the Treatment of Botulinum Neurotoxins A and B Intoxication. Toxicon51, 13. 10.1016/j.toxicon.2008.04.040

  • 35

    JaokoV.Nji Tizi TaningC.BackxS.MulatyaJ.Van den AbeeleJ.MagomereT.et al (2020). The Phytochemical Composition of Melia Volkensii and its Potential for Insect Pest Management. Plants (Basel)9. 10.3390/plants9020143

  • 36

    JinY.HuangZ. L.LiL.YangY.WangC. H.WangZ. T.et al (2019b). Quercetin Attenuates Toosendanin-Induced Hepatotoxicity through Inducing the Nrf2/GCL/GSH Antioxidant Signaling Pathway. Acta Pharmacol. Sin.40, 7585. 10.1038/s41401-018-0024-8

  • 37

    JinY. H.KwonS.ChoiJ. G.ChoW. K.LeeB.MaJ. Y. (2019a). Toosendanin from Melia Fructus Suppresses Influenza A Virus Infection by Altering Nuclear Localization of Viral Polymerase PA Protein. Front. Pharmacol.10, 1025. 10.3389/fphar.2019.01025

  • 38

    JuJ.QiZ.CaiX.CaoP.HuangY.WangS.et al (2012). The Apoptotic Effects of Toosendanin Are Partially Mediated by Activation of Deoxycytidine Kinase in HL-60 Cells. Plos One7, e52536. 10.1371/journal.pone.0052536

  • 39

    JuJ.QiZ.CaiX.CaoP.LiuN.WangS.et al (2013). Toosendanin Induces Apoptosis through Suppression of JNK Signaling Pathway in HL-60 Cells. Toxicol. Vitro27, 232238. 10.1016/j.tiv.2012.09.013

  • 40

    KaiW.YatingS.LinM.KaiyongY.BaojinH.WuY.et al (2018). Natural Product Toosendanin Reverses the Resistance of Human Breast Cancer Cells to Adriamycin as a Novel PI3K Inhibitor. Biochem. Pharmacol.152, 153164. 10.1016/j.bcp.2018.03.022

  • 41

    LiH.ZhangJ.MaT.LiC.MaZ.ZhangX. (2020a). Acting Target of Toosendanin Locates in the Midgut Epithelium Cells of Mythimna Separate Walker Larvae (Lepidoptera: Noctuidae). Ecotoxicol. Environ. Saf.201, 110828. 10.1016/j.ecoenv.2020.110828

  • 42

    LiM. F.ShiY. L. (2005). The Long-Term Effect of Toosendanin on Current through Nifedipine-Sensitive Ca2+ Channels in NG108-15 Cells. Toxicon45, 5360. 10.1016/j.toxicon.2004.09.010

  • 43

    LiM. F.ShiY. L. (2006). Toosendanin Interferes with Pore Formation of Botulinum Toxin Type A in PC12 Cell Membrane. Acta Pharmacol. Sin.27, 6670. 10.1111/j.1745-7254.2006.00236.x

  • 44

    LiM. F.ShiY. L. (2004). Toosendanin, a Triterpenoid Derivative, Acts as a Novel Agonist of L-type Ca2+ Channels in Neonatal Rat Ventricular Cells. Eur. J. Pharmacol.501, 7178. 10.1016/j.ejphar.2004.08.027

  • 45

    LiP. Z.SunG. Z. (1983). Antagonistic Effect of Toosendanin to Botulinum Toxin on Neuromuscular Preparations of Mice. Acta Physiol. Sinica.4, 480483.

  • 46

    LiS.LiY.XuR.KongL. Y.LuoJ. (2020b). New Meliacarpin-type (C-Seco) and C-Ring Intact Limonoids from the Fruits of Melia Toosendan. Fitoterapia144, 104605. 10.1016/j.fitote.2020.104605

  • 47

    LiS.LiY.XuR.KongL. Y.LuoJ.ZhuX. M.et al (2020). New Meliacarpin-type (C-Seco) and C-Ring Intact Limonoids from the Fruits of Melia Toosendan. Fitoterapia144, 104605104622. 10.1016/j.fitote.2020.104605

  • 48

    LiX.YouM.LiuY. J.MaL.JinP. P.ZhouR.et al (2017). Reversal of the Apoptotic Resistance of Non-small-cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin. Sci. Rep.7, 42748. 10.1038/srep42748

  • 49

    LiY. Y.JinL. T.LinJ. T.DingY. M.YaoS. H. (2018a). Effect of Toosendanin on the Apoptosis of Human Ovarian Cancer Cells through Mitochondrial Pathway. Chin. Pharm. J.2, 109113. 10.11669/cpj.2018.02.007

  • 50

    LiY. Y.ShaoX. Y.JinL. T.LiQ. F.ChenX. M. (2019). Apoptosis of Ovarian Cancer Cells Induced by Toosendanin through Fas/FasL Signaling Pathway. Chin. J. Integr. Trad. West. Med.9, 10891094. 10.7661/j.cjim.20190729.089

  • 51

    LiY. Y.ZhangK. N.CaiJ. W.LinJ. T.ShaoX. Y. (2018b). Effect of Toosendanin on Invasion and Migration of Human Ovarian Cancer Cells. Chin. J. Pathophysiol.1, 7074. 10.3969/j.issn.1000-4718.2018.01.012

  • 52

    Li-WeberM. (2013). Targeting Apoptosis Pathways in Cancer by Chinese Medicine. Cancer Lett.332, 304312. 10.1016/j.canlet.2010.07.015

  • 53

    LianX.ZhangX.WangF.WangX.XueZ.QiX. (2020). Characterization of a 2,3-oxidosqualene Cyclase in the Toosendanin Biosynthetic Pathway of Melia Toosendan. Physiol. Plant170, 528536. 10.1111/ppl.13189

  • 54

    LiuH.LiuY.BianZ.ZhangJ.ZhangR.ChenX.et al (2019). Correction to: Circular RNA YAP1 Inhibits the Proliferation and Invasion of Gastric Cancer Cells by Regulating the miR-367-5p/p27 Kip1 axis. Mol. Cancer18, 117. 10.1186/s12943-019-1045-8

  • 55

    LiuH. B.ZhangC. R.DongS. H.DongL.WuY.YueJ. M. (2011). Limonoids and Triterpenoids from the Seeds of Melia Azedarach. Chem. Pharm. Bull. (Tokyo)59, 10031007. 10.1248/cpb.59.1003

  • 56

    LiuS. C.TangW. Z.MaT.YaoQ. Q. (2010). Review on Studies of the Chemical Constituents and Pharmcological Activities of Melia L. Qilu Pharm. Aff.5, 290293. 10.3969/j.issn.1672-7738.2010.05.017

  • 57

    LiuX. L.WangH.ZhangL.WangY. L.WangJ.WangP.et al (2016). Anticancer effects of crude extract from Melia toosendan Sieb. et Zucc on hepatocellular carcinoma In Vitro and In Vivo. Chin. J. Integr. Med.22, 362369. 10.1007/s11655-015-2084-7

  • 58

    LuX.JiC.TongW.LianX.WuY.FanX.et al (2016). Integrated Analysis of microRNA and mRNA Expression Profiles Highlights the Complex and Dynamic Behavior of Toosendanin-Induced Liver Injury in Mice. Sci. Rep.6, 34225. 10.1038/srep34225

  • 59

    LuoW.LiuX.SunW.LuJ. J.WangY.ChenX. (2018). Toosendanin, a Natural Product, Inhibited TGF-Β1-Induced Epithelial-Mesenchymal Transition through ERK/Snail Pathway. Phytother. Res.32, 20092020. 10.1002/ptr.6132

  • 60

    MaZ.Gulia-NussM.ZhangX.BrownM. R. (2013). Effects of the Botanical Insecticide, Toosendanin, on Blood Digestion and Egg Production by Female Aedes aegypti (Diptera: Culicidae): Topical Application and Ingestion. J. Med. Entomol.50, 112121. 10.1603/me12119

  • 61

    MadyasthaK. M.VenkatakrishnanK. (2000). Structural Flexibility in the Biocatalyst-Mediated Functionalization of Ring 'A' in Salannin, a Tetranortriterpene from Azadirachta indica. J. Chem. Soc. Perkin Trans. 1118, 30553062. 10.1039/b004260i

  • 62

    NakaiY.PellettS.TeppW. H.JohnsonE. A.JandaK. D. (2010). Toosendanin: Synthesis of the AB-Ring and Investigations of its Anti-botulinum Properties (Part II). Bioorg. Med. Chem.18, 12801287. 10.1016/j.bmc.2009.12.030

  • 63

    NakaiY.TeppW. H.DickersonT. J.JohnsonE. A.JandaK. D. (2009). Function-oriented Synthesis Applied to the Anti-botulinum Natural Product Toosendanin. Bioorg. Med. Chem.17, 11521157. 10.1016/j.bmc.2008.12.042

  • 64

    NakataniM.Chun HuangR.OkamuraH.NaokiH.IwagawaT. (1994). Limonoid Antifeedants from Chinese Melia Azedarach. Phytochemistry36, 3941. 10.1016/s0031-9422(00)97008-0

  • 65

    NakataniM.FukumanY.SakumotoT.YamashitaN.OkamuraH.IwagawaT. (2000). Nimbolinins, C-Seco Limonoids from the Fruits of Melia Toosendan. Heterocycles53, 689. 10.3987/com-99-8768

  • 66

    NakataniM.HuangR. C.OkamuraH.IwagawaT. (1993). The Structure of a New Antifeeding Meliacarpinin from ChinesMelia azedarachL. Chem. Lett.22, 21252128. 10.1246/cl.1993.2125

  • 67

    NakataniM. (1999). Limonoids from Melia Toosendan (Meliaceae) and Their Antifeedant Activity. Heterocycles50, 595609. 10.3987/rev-98-sr(h)5

  • 68

    NakataniM.ShimokoroM.ZhouJ.-B.OkamuraH.IwagawaT.TaderaK.et al (1999). Limonoids from Melia Toosendan. Phytochemistry52, 709714. 10.1016/s0031-9422(99)00332-5

  • 69

    NakataniM.ZhouJ.-B.NakayamaN.OkamuraH.IwagawaT. (1996). Nimbolidins C-E, Limonoid Antifeedants from Melia Toosendan. Phytochemistry41, 739743. 10.1016/0031-9422(95)00696-6

  • 70

    OchiM.KotsukiH.IdoM.NakaiH.ShiroM.TokoroyamaT. (1979). The Structures of Ohchinolide a and B, Two New Limonoids Frommelia Azedarachlinn.Var. Japonicamakino. Chem. Lett.8, 11371140. 10.1246/cl.1979.1137

  • 71

    OlaM. S.NawazM.AhsanH. (2011). Role of Bcl-2 Family Proteins and Caspases in the Regulation of Apoptosis. Mol. Cell. Biochem.351, 4158. 10.1007/s11010-010-0709-x

  • 72

    OrreniusS.ZhivotovskyB.NicoteraP. (2003). Regulation of Cell Death: the Calcium-Apoptosis Link. Nat. Rev. Mol. Cel Biol4, 552565. 10.1038/nrm1150

  • 73

    OttoT.SicinskiP. (2017). Cell Cycle Proteins as Promising Targets in Cancer Therapy. Nat. Rev. Cancer17, 93115. 10.1038/nrc.2016.138

  • 74

    PanX.MatsumotoM.NakamuraY.KikuchiT.ZhangJ.UkiyaM.et al (2014a). Three New and Other Limonoids from the Hexane Extract of Melia Azedarach Fruits and Their Cytotoxic Activities. Chem. Biodivers.11, 9871000. 10.1002/cbdv.201400052

  • 75

    PanX.MatsumotoM.NishimotoY.OgiharaE.ZhangJ.UkiyaM.et al (2014b). Cytotoxic and Nitric Oxide Production-Inhibitory Activities of Limonoids and Other Compounds from the Leaves and Bark of Melia Azedarach. Chem. Biodivers.11, 11211139. 10.1002/cbdv.201400190

  • 76

    ParkS.NhiemN. X.SubediL.OhI.KimJ. Y.KimS. Y.et al (2020). Isolation of Bioactive Limonoids from the Fruits of Melia Azedarach. J. Asian Nat. Prod. Res.22, 830838. 10.1080/10286020.2019.1666826

  • 77

    PeiZ.FuW.WangG. (2017). A Natural Product Toosendanin Inhibits Epithelial-Mesenchymal Transition and Tumor Growth in Pancreatic Cancer via Deactivating Akt/mTOR Signaling. Biochem. Biophys. Res. Commun.493, 455460. 10.1016/j.bbrc.2017.08.170

  • 78

    QiuL.HengL.XuR.LuoJ.LiY. (2019). Two New Nimbolinin- and Trichilin-Class Limonoids Isolated from the Fruits of Melia Azedarach. Chin. J. Nat. Med.17, 227230. 10.1016/s1875-5364(19)30025-1

  • 79

    RizzutoR.PintonP.FerrariD.ChamiM.SzabadkaiG.MagalhãesP. J.et al (2003). Calcium and Apoptosis: Facts and Hypotheses. Oncogene22, 86198627. 10.1038/sj.onc.1207105

  • 80

    RogersL. L.ZengL.KozlowskiJ. F.ShimadaH.AlaliF. Q.JohnsonH. A.et al (1998a). New Bioactive Triterpenoids from Melia Volkensii. J. Nat. Prod.61, 6470. 10.1021/np9704009

  • 81

    RogersL. L.ZengL.McLaughlinJ. L. (1998b). Volkensinin: A New Limonoid from Melia Volkensii. Tetrahedron Lett.39, 46234626. 10.1016/s0040-4039(98)00854-5

  • 82

    RossettoO.PirazziniM.MontecuccoC. (2014). Botulinum Neurotoxins: Genetic, Structural and Mechanistic Insights. Nat. Rev. Microbiol.12, 535549. 10.1038/nrmicro3295

  • 83

    SachdevaM.MoY. Y. (2010). MicroRNA-145 Suppresses Cell Invasion and Metastasis by Directly Targeting Mucin 1. Cancer Res.70, 378387. 10.1158/0008-5472.can-09-2021

  • 84

    SaleemS.MuhammadG.HussainM. A.BukhariS. N. A. (2018). A Comprehensive Review of Phytochemical Profile, Bioactives for Pharmaceuticals, and Pharmacological Attributes of Azadirachta indica. Phytother. Res.32, 12411272. 10.1002/ptr.6076

  • 85

    ShaoS.LiS.LiuC.ZhangW.ZhangZ.ZhuS.et al (2020). Toosendanin Induces Apoptosis of MKN45 Human Gastric Cancer Cells Partly through miR23a3pmediated Downregulation of BCL2. Mol. Med. Rep.22, 17931802. 10.3892/mmr.2020.11263

  • 86

    ShenL. Q.PengF.CaiJ. N.LiuJ. Y.HaoL. L.FengY. L.et al (2014). Fingerprint Analysis of Limonoids in Fructus Toosendan by HPLC-ELSD. Chin. J. Pharm. Anal.8, 14311434. 10.16155/j.0254-1793.2014.08.007

  • 87

    ShiY. L.LiM. F. (2007). Biological Effects of Toosendanin, a Triterpenoid Extracted from Chinese Traditional Medicine. Prog. Neurobiol.82, 110. 10.1016/j.pneurobio.2007.02.002

  • 88

    ShiY. L.WangW. P.YanS. C.XuK. (1982). Effects of Calcium Ions and Nerve Impulses on Changes in Miniature End-Plate Potential Frequency Produced by Toosendanin. Acta Physiol. Sinica.3, 304309.

  • 89

    ShihY. L.HsuK. (1983). Anti-botulismic Effect of Toosendanin and its Facilitatory Action on Miniature End-Plate Potentials. Jpn. J. Physiol.33, 677680. 10.2170/jjphysiol.33.677

  • 90

    SiddiquiW. A.AhadA.AhsanH. (2015). The Mystery of BCL2 Family: Bcl-2 Proteins and Apoptosis: an Update. Arch. Toxicol.89, 289317. 10.1007/s00204-014-1448-7

  • 91

    SinghN.HassanA.BoseK. (2016). Molecular Basis of Death Effector Domain Chain Assembly and its Role in Caspase-8 Activation. FASEB J.30, 186200. 10.1096/fj.15-272997

  • 92

    SuG. X.LiangX. T. (1980). A Correction of the Structure of Chuanliansu. Acta Chim. Sinica.2, 196198.

  • 93

    SuS.ShenL.ZhangY.LiuJ.CaiJ.HaoL.et al (2013). Characterization of Tautomeric Limonoids from the Fruits of Melia Toosendan. Phytochemistry Lett.6, 418424. 10.1016/j.phytol.2013.05.006

  • 94

    SuZ.-S.YangS.-P.ZhangS.DongL.YueJ.-M. (2011). Meliarachins A-K: Eleven Limonoids from the Twigs and Leaves of Melia Azedarach. Hca94, 15151526. 10.1002/hlca.201000444

  • 95

    TadaK.TakidoM.KitanakaS. (1999). Limonoids from Fruit of Melia Toosendan and Their Cytotoxic Activity. Phytochemistry51, 787791. 10.1016/s0031-9422(99)00115-6

  • 96

    TakeyaK.QiaoZ. S.HirobeC.ItokawaH. (1996a). Cytotoxic Azadirachtin-type Limonoids from Melia Azedarach. Phytochemistry42, 709712. 10.1016/0031-9422(96)00044-1

  • 97

    TakeyaK.QuioZ. S.HirobeC.ItokawaH. (1996b). Cytotoxic Trichilin-type Limonoids from Melia Azedarach. Bioorg. Med. Chem.4, 13551359. 10.1016/0968-0896(96)00128-9

  • 98

    TanQ. G.LuoX. D. (2011). Meliaceous Limonoids: Chemistry and Biological Activities. Chem. Rev.111, 74377522. 10.1021/cr9004023

  • 99

    TangM. Z.WangZ. F.ShiY. L. (2004). Involvement of Cytochrome C Release and Caspase Activation in Toosendanin-Induced PC12 Cell Apoptosis. Toxicology201, 3138. 10.1016/j.tox.2004.03.023

  • 100

    TaoL.ZhangF.HaoL.WuJ.JiaJ.LiuJ. Y.et al (2014). 1-O-tigloyl-1-O-deacetyl-nimbolinin B Inhibits LPS-Stimulated Inflammatory Responses by Suppressing NF-κB and JNK Activation in Microglia Cells. J. Pharmacol. Sci.125, 364374. 10.1254/jphs.14025FP

  • 101

    TaylorD. A. H. (1984). The Chemistry of the Limonoids from Meliaceae. Prog. Chem. Org. Nat. Prod.45, 1102. 10.1007/978-3-7091-8717-3_1

  • 102

    TummersB.GreenD. R. (2017). Caspase-8: Regulating Life and Death. Immunol. Rev.277 (1), 7689. 10.1111/imr.12541

  • 103

    WajantH. (2002). The Fas Signaling Pathway: More Than a Paradigm. Science296, 16351636. 10.1126/science.1071553

  • 104

    WangG.FengC. C.ChuS. J.ZhangR.LuY. M.ZhuJ. S.et al (2015). Toosendanin Inhibits Growth and Induces Apoptosis in Colorectal Cancer Cells through Suppression of AKT/GSK-3β/β-catenin Pathway. Int. J. Oncol.47, 17671774. 10.3892/ijo.2015.3157

  • 105

    WangG.HuangY.-X.ZhangR.HouL.-D.LiuH.ChenX.-Y.et al (2017). Toosendanin Suppresses Oncogenic Phenotypes of Human Gastric Carcinoma SGC-7901 Cells Partly via miR-200a-Mediated Downregulation of β-catenin Pathway. Int. J. Oncol.51, 15631573. 10.3892/ijo.2017.4139

  • 106

    WangH.DongH. Y.HeQ. M.LiangJ. L.ZhaoT.ZhouL. (2020a). Characterization of Limonoids Isolated from the Fruits of Melia Toosendan and Their Antifeedant Activity against Pieris Rapae. Chem. Biodivers.17, e1900674. 10.1002/cbdv.201900674

  • 107

    WangH.WenC.ChenS.WangF.HeL.LiW.et al (2020b). Toosendanin-induced Apoptosis in Colorectal Cancer Cells Is Associated with the κ-opioid Receptor/β-Catenin Signaling axis. Biochem. Pharmacol.177, 114014. 10.1016/j.bcp.2020.114014

  • 108

    WangQ.WangZ.HouG.HuangP. (2020c). Toosendanin Suppresses Glioma Progression Property and Induces Apoptosis by Regulating miR-608/Notch Axis. Cancer Manag. Res.12, 34193431. 10.2147/cmar.s240268

  • 109

    WangX.WangC.WangZ. (2013). Determination of Toosendanin in Rat Plasma by Ultra-performance Liquid Chromatography-Electrospray Ionization-Mass Spectrometry and its Application in a Pharmacokinetic Study. Biomed. Chromatogr.27, 222227. 10.1002/bmc.2779

  • 110

    WatanabeT.SakamotoN.NakagawaM.KakinumaS.ItsuiY.Nishimura-SakuraiY.et al (2011). Inhibitory Effect of a Triterpenoid Compound, with or without Alpha Interferon, on Hepatitis C Virus Infection. Antimicrob. Agents Chemother.55, 25372545. 10.1128/aac.01780-10

  • 111

    WenderP. A. (2013). Toward the Ideal Synthesis and Transformative Therapies: the Roles of Step Economy and Function Oriented Synthesis. Tetrahedron69 (36), 75297550. 10.1016/j.tet.2013.06.004

  • 112

    WhitfieldM. L.GeorgeL. K.GrantG. D.PerouC. M. (2006). Common Markers of Proliferation. Nat. Rev. Cancer6, 99106. 10.1038/nrc1802

  • 113

    WuJ. L.LeungE. L.ZhouH.LiuL.LiN. (2013). Metabolite Analysis of Toosendanin by an Ultra-high Performance Liquid Chromatography-Quadrupole-Time of Flight Mass Spectrometry Technique. Molecules18, 1214412153. 10.3390/molecules181012144

  • 114

    XieF.ZhangM.ZhangC. F.WangZ. T.YuB. Y.KouJ. P. (2008). Anti-inflammatory and Analgesic Activities of Ethanolic Extract and Two Limonoids from Melia Toosendan Fruit. J. Ethnopharmacol.117, 463466. 10.1016/j.jep.2008.02.025

  • 115

    XieY. S.FieldsP. G.IsmanM. B.ChenW. K.ZhangX. (1995). Insecticidal Activity of Melia Toosendan Extracts and Toosendanin against Three Stored-Product Insects. J. Stored Prod. Res.31, 259265. 10.1016/0022-474x(95)00003-p

  • 116

    XiongC. S. (1985). The Interaction between Toosendanin and Botulinum Toxin at the Neuromuscular junction, an Ultrastructure Observation. Acta Pharm. Sin.7, 495499.

  • 117

    XuH.ZhangJ. L. (2011). Natural Products-Based Insecticidal Agents 9. Design, Semisynthesis and Insecticidal Activity of 28-acyloxy Derivatives of Toosendanin against Mythimna Separata Walker In Vivo. Bioorg. Med. Chem. Lett.21, 19741977. 10.1016/j.bmcl.2011.02.031

  • 118

    XuR.ZhangL.LiuJ. (2019). The Natural Triterpenoid Toosendanin as a Potential Control Agent of the Ciliate Stylonychia mytilus in Microalgal Cultures. J. Appl. Phycol.31, 4148. 10.1007/s10811-018-1522-2

  • 119

    YanX.ZhuoY.BianX.LiJ.ZhangY.MaL.et al (2019). Integrated Proteomics, Biological Functional Assessments, and Metabolomics Reveal Toosendanin-Induced Hepatic Energy Metabolic Disorders. Chem. Res. Toxicol.32, 668680. 10.1021/acs.chemrestox.8b00350

  • 120

    YangF.LiL.YangR.WeiM.ShengY.JiL. (2019). Identification of Serum microRNAs as Potential Toxicological Biomarkers for Toosendanin-Induced Liver Injury in Mice. Phytomedicine58, 152867. 10.1016/j.phymed.2019.152867

  • 121

    YuJ.DengP.ZhongD.ChenX. (2014). Identification of Amino Acid and Glutathione N-Conjugates of Toosendanin: Bioactivation of the Furan Ring Mediated by CYP3A4. Chem. Res. Toxicol.27, 15981609. 10.1021/tx5002145

  • 122

    YuJ.ZhangR.ZhangT.ZhaoJ.ZhangY.WangQ.et al (2020). Determination of Toosendanin and Trans-anethole in Fructus Meliae Toosendan and Fructus Foeniculi by HPLC-MS/MS and GC-MS/MS in Rat Plasma and Their Potential Herb-Herb Interactions. Biomed. Chromatogr.34, e4837. 10.1002/bmc.4837

  • 123

    YuanC. M.ZhangY.TangG. H.LiY.HeH. P.LiS. F.et al (2013). Cytotoxic Limonoids from Melia Azedarach. Planta Med.79, 163168. 10.1055/s-0032-1328069

  • 124

    ZengL.GuZ.-m.FangX.-p.FanwickP. E.ChangC.-j.SmithD. L.et al (1995a). Two New Bioactive Triterpenoids from Melia Volkensii (Meliaceae). Tetrahedron51, 24772488. 10.1016/0040-4020(95)00018-4

  • 125

    ZengL.GuZ. M.FanwickP. E.ChangC. J.SmithD. L.McLaughlinJ. L. (1995b). Additional Bioactive Triterpenoids from Melia-Volkensii (Meliaceae). Heterocycles41, 741752.

  • 126

    ZhangB.WangZ. F.TangM. Z.ShiY. L. (2005a). Growth Inhibition and Apoptosis-Induced Effect on Human Cancer Cells of Toosendanin, a Triterpenoid Derivative from Chinese Traditional Medicine. Invest. New Drugs23, 547553. 10.1007/s10637-005-0909-5

  • 127

    ZhangJ. L.ShiW. Y.ZhongW.MaA. T.WangX. D.ZhaoY. T.et al (2010a). Effects of Toosendanin on Pregnancy and Uterine Immunity Alterations in Mice. Am. J. Chin. Med.38, 319328. 10.1142/s0192415x10007877

  • 128

    ZhangQ.LiJ. K.GeR.LiangJ. Y.LiQ. S.MinZ. D. (2013). Novel NGF-Potentiating Limonoids from the Fruits of Melia Toosendan. Fitoterapia90, 192198. 10.1016/j.fitote.2013.07.019

  • 129

    ZhangQ.LiQ. S.LiangJ. Y.MinZ. D. (2010d). Limonoids from Fruits of Melia Toosendan. Yao Xue Xue Bao45, 475478. 10.16438/j.0513-4870.2010.04.006

  • 130

    ZhangQ.ShiY.LiuX. T.LiangJ. Y.IpN. Y.MinZ. D. (2007). Minor Limonoids from Melia Toosendan and Their Antibacterial Activity. Planta Med.73 (12), 12981303. 10.1055/s-2007-981618

  • 131

    ZhangQ.ZhengQ. H.LiangJ. Y.LiQ. S.MinZ. D. (2016). Two New Limonoids Isolated from the Fuits of Melia Toosendan. Chin. J. Nat. Med.14, 692696. 10.1016/s1875-5364(16)30082-6

  • 132

    ZhangQ.ZhengQ. H.SangY. S.SungH. H.MinZ. D. (2018). New Limonoids Isolated from the Bark of Melia Toosendan. Chin. J. Nat. Med.16, 946950. 10.1016/S1875-5364(18)30136-5

  • 133

    ZhangQ.LiangJ. Y.LiQ. S.Da MinZ. (2010b). New Limonoids from the Fruits of Melia Toosendan. Chin. Chem. Lett.21, 838841. 10.1016/j.cclet.2010.02.018

  • 134

    ZhangW. M.LiuJ. Q.PengX. R.WanL. S.ZhangZ. R.LiZ. R.et al (2014). Triterpenoids and Sterols from the Leaves and Twigs of Melia Azedarach. Nat. Prod. Bioprospect.4, 157162. 10.1007/s13659-014-0019-1

  • 135

    ZhangX. F.WangJ. H.ZhangS. F.LiuY.FanL. C.ShiX. Y. (2005b). Research of Embryotoxicity of Toosendanin in Kunming Mice. Acta Vet. Zootechnica Sinica3, 301305. 10.3321/j.issn:0366-6964.2005.03.020

  • 136

    ZhangX.ZhaoS. H. (1992a). Effect of Toosendanin on Several Enzyme Systems of the Cabbage Worm Pieris Rapae L. Acta Entomol. Sinica.2, 171177.

  • 137

    ZhangX.ZhaoS. H. (1992b). Effect of Toosendanin on the Respiration and Other Physiological Parameters of the Imported Cabbage Worm (Pieris Rapae L). J. South. China Agr. Univ.2, 511.

  • 138

    ZhangX.ZhaoS. H. (1991). Studies on the Histopathology of the Midgut of Cabbageworm Pieris Rapae L. Caused by Toosendanin. Acta Entomol. Sinica.4, 501502.

  • 139

    ZhangY.QiX.GongL.LiY.LiuL.XueX.et al (2008). Roles of Reactive Oxygen Species and MAP Kinases in the Primary Rat Hepatocytes Death Induced by Toosendanin. Toxicology249, 6268. 10.1016/j.tox.2008.04.005

  • 140

    ZhangY.TangC. P.KeC. Q.LiX. Q.XieH.YeY. (2012). Limonoids from the Fruits of Melia Toosendan. Phytochemistry73, 106113. 10.1016/j.phytochem.2011.10.001

  • 141

    ZhangY.TangC. P.KeC. Q.YaoS.YeY. (2010c). Limonoids and Triterpenoids from the Stem Bark of Melia Toosendan. J. Nat. Prod.73, 664668. 10.1021/np900835k

  • 142

    ZhaoL.HuoC. H.ShenL. R.YangY.ZhangQ.ShiQ. W. (2010). Chemical Constituents of Plants from the Genus Melia. Chem. Biodivers.7, 839859. 10.1002/cbdv.200900043

  • 143

    ZhaoQ.SongY.FengC.ChenH. (2012). Cytotoxic Tirucallane Triterpenoids from the Stem Bark of Melia Toosendan. Arch. Pharm. Res.35, 19031907. 10.1007/s12272-012-1106-7

  • 144

    ZhengM. D.WangN. D.LiX. L.YanJ.TangJ. H.ZhaoX. H.et al (2018). Toosendanin Mediates Cisplatin Sensitization through Targeting Annexin A4/ATP7A in Non-small Cell Lung Cancer Cells. J. Nat. Med.72, 724733. 10.1007/s11418-018-1211-0

  • 145

    ZhongC. C.XieJ. X.ChenS. F.LiangX. T. (1975). The Structure of Chuanliansu. Acta Chim. Sinica.1, 3547.

  • 146

    ZhouC.-Y.TangH.-Y.LiX.SangY.-S. (2009). Three New Limonoids fromMelia Toosendan. Hca92, 11911197. 10.1002/hlca.200800428

  • 147

    ZhouF.MaX. H.LiZ. J.LiW.ZhengW. M.WangZ. B.et al (2016). Four New Tirucallane Triterpenoids from the Fruits of Melia Azedarach and Their Cytotoxic Activities. Chem. Biodivers.13, 17381746. 10.1002/cbdv.201600149

  • 148

    ZhouH.HamazakiA.FontanaJ. D.TakahashiH.EsumiT.WandscheerC. B.et al (2004). New Ring C-Seco Limonoids from Brazilian Melia Azedarach and Their Cytotoxic Activity. J. Nat. Prod.67, 15441547. 10.1021/np040077r

  • 149

    ZhouH.HamazakiA.FontanaJ. D.TakahashiH.WandscheerC. B.FukuyamaY. (2005). Cytotoxic Limonoids from Brazilian Melia Azedarach. Chem. Pharm. Bull. (Tokyo)53, 13621365. 10.1248/cpb.53.1362

  • 150

    ZhouJ.-B.MinamiY.YagiF.TaderaK.NakataniM. (1997). Ring C-Seco Limonoids from Melia Toosendan. Phytochemistry46, 911914. 10.1016/s0031-9422(97)00378-6

  • 151

    ZhouJ.-B.OkamuraH.IwagawaT.NakataniM. (1996). Limonoid Antifeedants from Melia Toosendan. Phytochemistry41, 117120. 10.1016/0031-9422(95)00558-7

  • 152

    ZhouJ. B.TaderaK.MinamiY.YagiF.KurawakiJ.TakezakiK.et al (1998). New Limonoids from Melia Toosendan. Biosci. Biotechnol. Biochem.62, 496500. 10.1271/bbb.62.496

  • 153

    ZhouJ. Y.WangZ. F.RenX. M.TangM. Z.ShiY. L. (2003). Antagonism of Botulinum Toxin Type A-Induced Cleavage of SNAP-25 in Rat Cerebral Synaptosome by Toosendanin. FEBS Lett.555, 375379. 10.1016/s0014-5793(03)01291-2

  • 154

    ZhouQ.WuX.WenC.WangH.WangH.LiuH.et al (2018). Toosendanin Induces Caspase-dependent Apoptosis through the P38 MAPK Pathway in Human Gastric Cancer Cells. Biochem. Biophysical Res. Commun.505, 261266. 10.1016/j.bbrc.2018.09.093

  • 155

    ZhuG. Y.BaiL. P.LiuL.JiangZ. H. (2014). Limonoids from the Fruits of Melia Toosendan and Their NF-κB Modulating Activities. Phytochemistry107, 175181. 10.1016/j.phytochem.2014.08.009

  • 156

    ZouJ.YeH. J.HeX. Y.YuY. X.XiaZhangH. Q. L. S.ZhangA. P.et al (1985). The Therapeutic Effect of Orally Administrated Toosendanin on Human Botulism. Mil. Med. Sci.37, 307310.

Summary

Keywords

limonoids, genus Melia, toosendanin, anti-tumor, insecticide, toxicology

Citation

Fan W, Fan L, Wang Z and Yang L (2022) Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology. Front. Pharmacol. 12:795565. doi: 10.3389/fphar.2021.795565

Received

15 October 2021

Accepted

06 December 2021

Published

24 January 2022

Volume

12 - 2021

Edited by

Lyndy Joy McGaw, University of Pretoria, South Africa

Reviewed by

Guozheng Huang, Anhui University of Technology, China

Jung Chao, China Medical University, Taiwan

Chengjian Zheng, Second Military Medical University, China

Updates

Copyright

*Correspondence: Zhengtao Wang, ; Li Yang,

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics